<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680831-A1" country="EP" doc-number="2680831" kind="A1" date="20140108" family-id="45787198" file-reference-id="252638" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586830" ucid="EP-2680831-A1"><document-id><country>EP</country><doc-number>2680831</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12706831-A" is-representative="NO"><document-id mxw-id="PAPP154849022" load-source="docdb" format="epo"><country>EP</country><doc-number>12706831</doc-number><kind>A</kind><date>20120228</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220440205" load-source="docdb" format="original"><country>EP</country><doc-number>12706831.0</doc-number><date>20120228</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140553459" ucid="EP-2012053378-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012053378</doc-number><kind>W</kind><date>20120228</date></document-id></priority-claim><priority-claim mxw-id="PPC140550120" ucid="SI-201100060-A" load-source="docdb"><document-id format="epo"><country>SI</country><doc-number>201100060</doc-number><kind>A</kind><date>20110228</date></document-id></priority-claim><priority-claim mxw-id="PPC140550442" ucid="SI-201100456-A" load-source="docdb"><document-id format="epo"><country>SI</country><doc-number>201100456</doc-number><kind>A</kind><date>20111209</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989316509" load-source="docdb">A61K  31/122       20060101AFI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989318211" load-source="docdb">A61K  31/416       20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989318336" load-source="docdb">A61K  31/505       20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989318432" load-source="docdb">A61K  31/415       20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989318557" load-source="docdb">A61K  31/4155      20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989318967" load-source="docdb">A61K  31/405       20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989319566" load-source="docdb">A61K  31/41        20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989319745" load-source="docdb">A61P   9/14        20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989319875" load-source="docdb">A61P   9/10        20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989319914" load-source="docdb">A61K  31/44        20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989320354" load-source="docdb">A61K  31/47        20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989320428" load-source="docdb">A61K  31/4015      20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989321935" load-source="docdb">A61K  31/366       20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989322330" load-source="docdb">A61K  31/422       20060101ALI20120921BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989322988" load-source="docdb">A61K  31/616       20060101ALI20120921BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989624054" load-source="docdb" scheme="CPC">A61K  31/505       20130101 LI20130422BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989626154" load-source="docdb" scheme="CPC">A61K  31/122       20130101 FI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989626421" load-source="docdb" scheme="CPC">A61K  31/4155      20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989626623" load-source="docdb" scheme="CPC">A61K  31/415       20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989629094" load-source="docdb" scheme="CPC">A61K  45/06        20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989630777" load-source="docdb" scheme="CPC">A61K  31/416       20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989632269" load-source="docdb" scheme="CPC">A61K  31/44        20130101 LI20130422BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989633261" load-source="docdb" scheme="CPC">A61K  31/41        20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989634172" load-source="docdb" scheme="CPC">A61K  31/422       20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989642474" load-source="docdb" scheme="CPC">A61K  31/366       20130101 LI20130422BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989647062" load-source="docdb" scheme="CPC">A61K  31/616       20130101 LI20130816BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989648347" load-source="docdb" scheme="CPC">A61K  31/4015      20130101 LI20130422BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989649550" load-source="docdb" scheme="CPC">A61K  31/405       20130101 LI20130422BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365123" lang="DE" load-source="patent-office">BEHANDLUNG VON ARTERIELLER ALTERUNG MITTELS RAAS-INHIBITOR</invention-title><invention-title mxw-id="PT132365124" lang="EN" load-source="patent-office">TREATMENT OF ARTERIAL AGEING BY RAAS INHIBITOR</invention-title><invention-title mxw-id="PT132365125" lang="FR" load-source="patent-office">TRAITEMENT DU VIEILLISSEMENT ARTÉRIEL PAR L'INHIBITEUR DE RAAS</invention-title><citations><non-patent-citations><nplcit><text>See references of WO 2012116996A1</text><sources><source mxw-id="PNPL67456170" load-source="docdb" name="SEA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919541364" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>FARMICOM PHARMACEUTICAL COMPANY D O O</last-name><address><country>SI</country></address></addressbook></applicant><applicant mxw-id="PPAR919506683" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>FARMICOM PHARMACEUTICAL COMPANY D.O.O.</last-name></addressbook></applicant><applicant mxw-id="PPAR919015415" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Farmicom Pharmaceutical Company D.O.O.</last-name><iid>101336358</iid><address><street>Obrtna Cona Logatec 30</street><city>1370 Logatec</city><country>SI</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919545705" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SABOVIC MISO</last-name><address><country>SI</country></address></addressbook></inventor><inventor mxw-id="PPAR919542633" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SABOVIC, MISO</last-name></addressbook></inventor><inventor mxw-id="PPAR919010400" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SABOVIC, MISO</last-name><address><street>Ulica Bratov Ucakar 46</street><city>1000 Ljubljana</city><country>SI</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919006279" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Latzel, Klaus</last-name><iid>101156613</iid><address><street>Latzel-IP Traunstrasse 3</street><city>81825 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012053378-W"><document-id><country>EP</country><doc-number>2012053378</doc-number><kind>W</kind><date>20120228</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012116996-A1"><document-id><country>WO</country><doc-number>2012116996</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549776882" load-source="docdb">AL</country><country mxw-id="DS549847031" load-source="docdb">AT</country><country mxw-id="DS549776884" load-source="docdb">BE</country><country mxw-id="DS549765674" load-source="docdb">BG</country><country mxw-id="DS549844967" load-source="docdb">CH</country><country mxw-id="DS549916745" load-source="docdb">CY</country><country mxw-id="DS549847032" load-source="docdb">CZ</country><country mxw-id="DS549776893" load-source="docdb">DE</country><country mxw-id="DS549916746" load-source="docdb">DK</country><country mxw-id="DS549916747" load-source="docdb">EE</country><country mxw-id="DS549846545" load-source="docdb">ES</country><country mxw-id="DS549765675" load-source="docdb">FI</country><country mxw-id="DS549765345" load-source="docdb">FR</country><country mxw-id="DS549776894" load-source="docdb">GB</country><country mxw-id="DS549916748" load-source="docdb">GR</country><country mxw-id="DS549776895" load-source="docdb">HR</country><country mxw-id="DS549847033" load-source="docdb">HU</country><country mxw-id="DS549844968" load-source="docdb">IE</country><country mxw-id="DS549916749" load-source="docdb">IS</country><country mxw-id="DS549765346" load-source="docdb">IT</country><country mxw-id="DS549916750" load-source="docdb">LI</country><country mxw-id="DS549765676" load-source="docdb">LT</country><country mxw-id="DS549860399" load-source="docdb">LU</country><country mxw-id="DS549765685" load-source="docdb">LV</country><country mxw-id="DS549765686" load-source="docdb">MC</country><country mxw-id="DS549860400" load-source="docdb">MK</country><country mxw-id="DS549860401" load-source="docdb">MT</country><country mxw-id="DS549776896" load-source="docdb">NL</country><country mxw-id="DS549765347" load-source="docdb">NO</country><country mxw-id="DS549765688" load-source="docdb">PL</country><country mxw-id="DS549844969" load-source="docdb">PT</country><country mxw-id="DS549776913" load-source="docdb">RO</country><country mxw-id="DS549844974" load-source="docdb">RS</country><country mxw-id="DS549765701" load-source="docdb">SE</country><country mxw-id="DS549846550" load-source="docdb">SI</country><country mxw-id="DS549765348" load-source="docdb">SK</country><country mxw-id="DS549765702" load-source="docdb">SM</country><country mxw-id="DS549916751" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99836280" ref-ucid="WO-2012116996-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to a pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group consisting of, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonistin in a subtherapeutic daily dose which is designed to prevent and/or to reduce the ageing of the body, particularly for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects.</p></abstract><abstract mxw-id="PA100332052" ref-ucid="WO-2012116996-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to a pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group consisting of, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonistin in a subtherapeutic daily dose which is designed to prevent and/or to reduce the ageing of the body, particularly for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects.</p></abstract><abstract mxw-id="PA99836281" ref-ucid="WO-2012116996-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne une composition de combinaisons pharmaceutiques comprenant au moins un inhibiteur du système rénine-angiotensine-aldostérone, sélectionné dans le groupe comprenant l'inhibiteur de la rénine, l'inhibiteur de l'enzyme de conversion de l'angiotensine et un antagoniste du récepteur de l'angiotensine II dans une dose quotidienne sous-thérapeutique. Ladite composition est conçue pour prévenir et/ou atténuer le vieillissement du corps, et peut être notamment utilisée dans la prévention, l'atténuation ou l'inversion du vieillissement artériel chez des sujets apparemment en bonne santé.</p></abstract><abstract mxw-id="PA100332053" ref-ucid="WO-2012116996-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne une composition de combinaisons pharmaceutiques comprenant au moins un inhibiteur du système rénine-angiotensine-aldostérone, sélectionné dans le groupe comprenant l'inhibiteur de la rénine, l'inhibiteur de l'enzyme de conversion de l'angiotensine et un antagoniste du récepteur de l'angiotensine II dans une dose quotidienne sous-thérapeutique. Ladite composition est conçue pour prévenir et/ou atténuer le vieillissement du corps, et peut être notamment utilisée dans la prévention, l'atténuation ou l'inversion du vieillissement artériel chez des sujets apparemment en bonne santé.</p></abstract><description mxw-id="PDES51233235" ref-ucid="WO-2012116996-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="3"/>--><p id="p0001" num="0001"> TREATMENT OF ARTERIAL AGEING </p><p id="p0002" num="0002"> BY RAAS INHIBITOR </p><p id="p0003" num="0003">Field of invention </p><p id="p0004" num="0004">The present invention relates to a pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose for use in the prevention, reduction or reversal of arterial aging in apparently healthy subjects. Further, the pharmaceutical composition according to the invention is also useful in decreasing the occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0005" num="0005">Background of invention Ageing (British English) or aging (American English) is the accumulation of changes in an organism or object over time. Ageing in humans refers to a multidimensional process of physical, psychological and social change. Ageing is defined as the gradual biological impairment of normal function, probably as a result of changes made to cells, molecules and tissues/morphological components. These changes have a direct impact on the functional ability of organs such as for example the heart, brain, kidney and lungs, biological systems such as for example the nervous, digestive and reproductive system and ultimately the organism as a whole. Although ageing affects the whole body the consequences of ageing are related to the involved organ or system. The ageing of arteries produces the most detrimental consequences of ageing. Ageing causes progressive decline in physiological arterial functions and morphology. Aged arteries generate changes in hemodynamic that importantly contribute to the development of cardiovascular diseases. In addition, aged arteries are more susceptible for the development of certa i n cond itions such as atherosclerosis. Taken all facts together, arterial ageing substantially contributes to the development of cardiovascular diseases such as for 
<!-- EPO <DP n="4"/>-->
 example, myocardial infarction, stroke, dementia, kidney failure, hypertension and similar. Thus, ageing, specifically arterial ageing, is one of most important risk factors for development of cardiovascular diseases. It is widely believed that ageing per se is not a modifiable risk factor. This conclusion does not necessarily apply to the arterial ageing, however. Cardiovascular diseases remain the leading cause of morbidity and mortality in developed countries despite current preventive strategies. Importantly, up to date, no effective treatment that would be able to prevent, reduce or even reverse the process of arterial ageing has been disclosed. Arterial ageing is characterised by alterations in cel ls, matrix, and biomolecules present in the arterial wall. Arterial ageing is a foundation for the initiation and progression of cardiovascular diseases. Although arterial ageing literary starts immediately after birth, it seems that important age- related changes occur at middle age. In this period (approximately between 20-65 years) age-related changes gradually and continuously progress. Basic representative functional and morphological age-related arterial changes are for example endothelial dysfunction, vascular smooth muscle cell proliferation/invasion/secretion, matrix fragmentation, collagenisation and glycation that result in typical age related changes such as for example increased arterial stiffness and decreased arterial wall elasticity. Age- associated arterial wall phenotype creates a microenvironment enriched with reactive oxygen species and inflammatory molecules. Several age-modified angiotensin II signalling molecules control and facilitate the processes producing age-related arterial changes. Age-related arterial changes are cl inically si lent, but as described above may lead to development of cardiovascular diseases. Targeting arterial ageing as soon as valuable can reduce the incidence/occurence and progression of said cardiovascular diseases. 
<!-- EPO <DP n="5"/>-->
 Arterial aging is a result of gradual changes of morphological (i.e. structural) and functional properties of the arterial wall. The arterial wall consists of three layers: intima, media and adventia. The most inner part of the arterial wall is endothelium (a part of intima), which is directly exposed to the blood in the artery lumen. There is a large amount of evidence providing that aging itself induces the stiffening of media and consequently the stiffening of whole arterial wall (morphological property) and the impairment of endothelial function (functional property). </p><p id="p0006" num="0006">It is well known in the art that arterial stiffness and endothelial dysfunction are among the most important mechanisms facilitating the development of cardiovascular disorders as hypertension, myocardial infarction, stroke, dementia, and similar. As regards the correlation between arterial aging, arterial stiffness, and cardiovascular risks, Mitchell at al. have found that increased arterial stiffness is a marker of increased cardiovascular risk, and arterial stiffness increases by aging. (Mitchell GF et al., Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation 2010; 121 :505-1 1 ). Thus, arterial aging, in particular affecting the gradual increase of arterial stiffness, increases the risk for cardiovascular disorders. </p><p id="p0007" num="0007">It is also well known in the art that one has to distinguish between arterial aging in apparently healthy subjects and arterial aging in connection with cardiovascular diseases (Najjar S. S. et al., Arterial Aging, Hypertension 2005; 46:454-462). When discussing apparently healthy subjects, Najjar et al. describe the changes in the arterial structure and function as part of "normative aging", whereas when discussing cardiovascular diseases, they refer to accelerated changes which is not comparable to normative ageing. Furthermore, J. M. Bowness reports that changes in the composition of the extracellular matrix associated with normal aging are clearly different from those occurring in the development of advanced atherosclerotic lesions (J. M. 
<!-- EPO <DP n="6"/>-->
 Bowness, Atherosclerosis and aging of the arterial wall, Can Med Assoc J 1992; 147(2):201 ). Moreover, H. -Y.Lee et al. disclose that arterial walls stiffen with age and that this aging process in the arterial tree is heterogeneous, with distal arteries not exhibiting these stiffening changes, which is different from the atherosclerotic process (H.-Y. Lee et a l . , Circulation Journal 2010; 94; 2258-2262). </p><p id="p0008" num="0008">The renin-angiotensin-aldosterone system (RAAS) plays an important role in regulating blood volume and systemic vascular resistance, which together influence cardiac output and arterial pressure. As the name implies, there are three important components to this system: renin, angiotensin, and aldosterone. Renin, which is primarily released by the kidneys, stimulates the formation of angiotensin in blood and tissues, which in turn stimulates the release of aldosterone from the adrenal cortex. When renin is released into the blood, it acts upon a circulating substrate, angiotensinogen, that undergoes proteolytic cleavage to form the decapeptide angiotensin I. Vascular endothelium, particularly in the lungs, has an enzyme, angiotensin converting enzyme (ACE), that cleaves off two amino acids to form the octapeptide, angiotensin II (All), although many other tissues in the body (heart, brain, vascular) also can form All. Renin inhibitors are antihypertensive drugs that inhibit the first and rate- limiting step of RAAS. Since the 1970s scientists have been trying to develop potent inhibitors with acceptable oral bioavailability. The first and second generations faced problems like poor bioavailability and lack of potency. The third generation is non-peptidic renin inhibitors with acceptable oral bioavailability and potency for clinical use in the treatment of hypertension. </p><p id="p0009" num="0009">Angiotensin-converting enzyme (ACE) inhibitors produce vasodilation by inhibiting the formation of angiotensin II. This vasoconstrictor is formed by the proteolytic action of renin (released by the kidneys) acting on circulating 
<!-- EPO <DP n="7"/>-->
 angiotensinogen to form angiotensin I. Angiotensin I is then converted to angiotensin II by angiotensin converting enzyme. ACE inhibitors also break down bradykinin (a vasodilator substance). Therefore, ACE inhibitors, by blocking the breakdown of bradykinin, increase bradykinin levels, which can contribute to the vasodilator action of ACE inhibitors. ACE inhibitors are used primarily to treat hypertension, they may also be prescribed for cardiac failure, diabetic nephropathy, renal disease, systemic sclerosis, left ventricular hypertrophy and other disorders. ACE inhibitors are often used in conjunction with a diuretic in treating hypertension and heart failure. Angiotensin I I receptor antagonists, also known as angiotensin receptor blockers (ARBs), AT1 -receptor antagonists or sartans, are a group of pharmaceuticals which modulate the renin-angiotensin-aldosterone system. Their main use is in hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes), congestive heart failure, proteinuria, and prevention of cardiac remodelling after myocardial infarction. ARBs are receptor antagonists that block type 1 angiotensin I I (AT1 ) receptors on bloods vessels and also in other tissues as arterial wall and heart muscle. ARBs act on the surface and inside arterial wall. Anti-inflammatory refers to the property of a substance or treatment that reduces inflammation. Anti-inflammatory substances should suppress the expression induction of inflammatory functional proteins such as enzyme participating in the production of chemical mediator of various cytokines and inflammation, as well as suppress information transfer in cells participating in activation, and/or suppress the action expression by chemical mediator of various cytokines and inflammation. </p><p id="p0010" num="0010">An antioxidant is known as a molecule that can neutralize free radicals by accepting or donating an electron to eliminate the unpaired condition. 
<!-- EPO <DP n="8"/>-->
 Typically this means that the antioxidant molecule becomes a free radical in the process of neutralizing a free radical molecule to a non-free-radical molecule. But the antioxidant molecule will usually be a much less reactive free radical than the free radical neutralized. Therefore, an antioxidant inhibits the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals. In turn, these radicals can start chain reactions that damage cells. Antioxidants terminate oxidation chain reactions by removing free radical intermediates, and inhibit other oxidation reactions. </p><p id="p0011" num="0011">Angiotensin II receptor antagonists and their therapeutically benefits for the primary indication are well known from the state of the art, for example numerous previous studies have shown that the angiotensin II receptor antagonist in therapeutic doses are effective in treatment of hypertension and cardiovascular disorders. The additional combinations with anti-inflammatory agents and/or antioxidants are known to be of certain treatment value for example for cardiovascular prevention (Antonpoulos AA et al. Recent Pat Cardiovasc Drug Disc 2009;4: 76-87). However, all the above mentioned references are silent on the effect on arterial ageing. Moreover, prior art does not teach or even does not give any hint that a subtherapeutic daily dose of these drugs is sufficient and efficient for prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0012" num="0012">WO 2005/072696 discloses the use of ACE (angiotensin-converting enzyme) inhibitors and/or angiotensin II receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing. The application is silent on the effect of said active substances on arterial ageing. </p><p id="p0013" num="0013">WO 2006/105806 discloses the composition comprising four or more active agents, namely a statin, a compound suppressing angiotensin production or 
<!-- EPO <DP n="9"/>-->
 activity and anti-inflammatory agent and at least one antioxidant used for prevention and/or treatment of ageing process. The application provides comparative data on a positive effect towards cell growth and cell reproduction when using the composition comprising all four above mentioned active agents. However, the application is silent on the impact of said combination on arterial ageing and it does not provide any data when one or more active agent is omitted from the composition. </p><p id="p0014" num="0014">Apparently novel approaches and strategies of prevention, reduction or reversal of arterial ageing are of great interest in view of the awareness that age, particularly arterial age is one of the most, if not, the most important risk factor for the development of cardiovascular disorders. Therefore, it would be a significant contribution to the art to provide an effective treatment of arterial ageing, this means treating functional and morphological changes of the arterial wall that are progressively developed during ageing per se. </p><p id="p0015" num="0015">It is known that angiotensin II receptor antagonists posses the so called pleiotropic effects this means effects beyond their primary action. Pleiotropic effects of a drug are actions other than those for which the agent was specifically developed. These effects maybe related or unrelated to the primary mechanism of action of the drug, and they are usually unexpected. </p><p id="p0016" num="0016">It is an object of the present invention to provide a pharmaceutical composition which is suitable to prevent, reduce or reverse arterial aging in apparently healthy subjects. </p><p id="p0017" num="0017">It is a further object of the present invention to provide a pharmaceutical composition which is suitable for improving the morphological properties of the arterial wall in apparently healthy subjects. 
<!-- EPO <DP n="10"/>-->
 It is a further object of the present invention to improve the functional properties of the arterial wall such as the endothelial function in apparently healthy subjects. It is a further object of the present invention to provide a composition which also provides a beneficial effect on the arterial aging after discontinuation of the treatment. It is a further object of the present invention to provide a pharmaceutical composition which allows for a decrease in the occurrence of cardiovascular diseases. </p><p id="p0018" num="0018">Summary of invention </p><p id="p0019" num="0019">The objects of the present invention are surprisingly achieved by providing a pharmaceutical composition comprising at least one renin-angiotensin- aldosterone system inhibitor in a subtherapeutic daily dose in the prevention, reduction or reversal of arterial aging in apparently healthy subjects. More specifically, the present invention relates to the pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant and combinations thereof for use in the prevention, reduction or reversal of arterial aging in apparently healthy subjects. An advantage of said pharmaceutical composition is a new approach for prevention of cardiovascular diseases. </p><p id="p0020" num="0020">Accordingly, the pharmaceutical combinations according to the present invention are also useful in decreasing the occurrence of cardiovascular disorders in apparently healthy subjects. 
<!-- EPO <DP n="11"/>-->
 In one aspect, the present invention is directed to a pharmaceutical composition composition comprising at least one renin-angiotensin- aldosterone system inhibitor in a subtherapeutic daily dose, in the prevention, reduction or reversal of arterial aging in apparently healthy subjects. </p><p id="p0021" num="0021">In a further aspect, the present invention is directed to a pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose for use in decreasing the occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0022" num="0022">As used herein the term "arterial aging" refers to changes, in particular gradual changes of morphological (i.e. structural) and functional properties of the arterial wall. Preferably "arterial aging" exclusively refers to changes, in particular gradual changes of the morphological properties of the arterial wall. </p><p id="p0023" num="0023">As used herein, the morphological properties of the arterial wall are preferably to be understood as the stiffness properties of arteries. Preferably, arterial stiffness can be determined on the basis of the parameters pulse wave velocity (PWV) and β-stiffness. Arterial stiffness is presently most adequately described by the parameter pulse wave velocity (PWV). The PWV is calculated from measurements of pulse transit time and the distance traveled by the pulse between two recording sites. Preferably, the PWV is measured on elastic arteries such as aorta, carotid artery, iliac artery, femoral artery. Thus, PWV represents the speed of pulse transmission through the arterial three. The stiffer the arteries are, the faster is the pulse transmission and consequently the higher is the PWV. The PWV can be easily and reproducibly measured using an ultrasound apparatus such as Aloka ProSound Alpha 10 apparatus with a high resolution eTracking system. Preferably the ultrasound apparatus is 
<!-- EPO <DP n="12"/>-->
 equipped with software for automatic determination of arterial stiffness parameters through the analysis of pulse waves. Other widely- used devices as Sphygomocor®, Compylor® and similar devices can also be used for PVW calculation. The β-stiffness is also a parameter being a measure for arterial stiffness. It describes the local arterial stiffness. Accordingly, the determination of β- stiffness is a method for measuring stiffness from artery diameter and mutation width by the beating and blood pressure. Preferably β-stiffness is measured using a common carotid artery using an ultrasound apparatus such as Aloka ProSound Alpha 10 apparatus with a high resolution eTracking system. Preferably the ultrasound apparatus is equipped with software for automatic determination of arterial stiffness parameters through the analysis of pulse waves. </p><p id="p0024" num="0024">As used herein, the functional properties of the arterial wall are preferably characterized by the endothelial function of the arterial wall. </p><p id="p0025" num="0025">Endothelial function can be assessed with a variety of methods. The most widely used method is the measurement of flow mediated dilatation (FMD) of brachial artery after short-term ischemia induced by sphygmomanometer inflation. Consequently, reactive hyperemia, which is dependent on endothelial function, occurs and brachial artery dilates. The present difference between the diameter measured after hyperemia and the basal diameter is taken as FMD. Generally FMD is used invasively with high- resolution ultrasound machines/systems; the measurements could be performed manually or automatically (as in the case when Aloka ProSound Alpha 10 apparatus is used). </p><p id="p0026" num="0026">In connection with "apparently healthy subjects" the term "arterial aging" preferably means that arterial aging in these subjects is not caused or 
<!-- EPO <DP n="13"/>-->
 accelerated by any extrinsic influence such as hypertension, metabolic syndrome, diabetes etc.. In this regard, reference is made to Figure 1 of the article by Lee et al. , wherein the causes of arterial aging are presented (H.-Y. Lee et al. , Circulation Journal 2010; 94; 2258-2262). </p><p id="p0027" num="0027">As used herein, "arterial aging" of "apparently healthy subjects" is preferably based on the structural change of the arteries with aging caused e.g. by longstanding arterial pulsation in the central artery, which has a direct effect on the structural matrix proteins, collagen and elastin in the arterial wall, disrupting muscular attachments and causing elastin fibers to fatigue and fracture. Further, accumulation of advanced glycation endproducts (AGE) on the proteins alters their physical properties and causes stiffness of the fibers in "apparently healthy subjects" . Sti ll further, the calcium content in the arterial wall increases with age in "apparently healthy subjects", which also contribute to arterial aging (H.-Y. Lee et al. , Circulation Journal 201 0; 94; 2258-2262). </p><p id="p0028" num="0028">As used herein, "apparently healthy subjects" are subjects, which have a low cardiovascular risk. An "apparently healthy subject" according to the present invention having a low cardiovascular risk exhibits a Framingham Risk Score for coronary heart disease (CHD) (10-year risk) of 10% or less, preferably 8% or less, more preferably 5% or less. The Fram ingham Risk Score for the CHD is calculated on the basis described in "The third report of the National Cholesterol Education Program (NCEP) Expert panel on Detection, Eval uation and Treatment of H igh B lood Cholesterol in Adults (Adu lt Treatment Panel III), Circulation 2002; 106: 3143-3421 . The calculation of the Framingham Risk Score for a coronary heart disease (CHD) (10-year risk) is based on the ATP III page of the NHLBI Web site (www.nhlbi.nih.gov/guidelines/cholesterol) referenced at page 3229 of said article. The algorithm underlying the calculation of the Fram ingham risk 
<!-- EPO <DP n="14"/>-->
 equation in these calculators has been described by Anderson KM et al. in "An updated coronary risk profile. A statement for health professionals", Circulation (1991 ), 83:356-362. With the Framingham risk score for the CHD (10 years) the risk for coronary heart diseases such as myocardial infarction and death is assessed. For the present invention, an apparently healthy man has a Framingham Risk Score for the CHD of 10% or less, preferably 8% or less, more preferably 5% or less and an apparently healthy woman has a Framingham Risk Score for the CHD of 10% or less, preferably 8% or less, more preferably 5% or less. </p><p id="p0029" num="0029">The parameters included in the Framigham risk score for a CHD are as follows: gender, age, total cholesterol level, HDL cholesterol level, smoking, systolic blood pressure and untreated/treated hypertension. </p><p id="p0030" num="0030">An apparently healthy subject having a low cardiovascular risk does preferably not have a (manifested) cardiovascular disorder. More preferably, the apparently healthy subject does not have diabetes. </p><p id="p0031" num="0031">In another preferred embodiment, the apparently healthy subject does not have a (manifested) cardiovascular disorder and in addition does not have disorders which importantly influence the functional capacity of different tissues/organs or the whole body. </p><p id="p0032" num="0032">The term cardiovascular disorder (CVD) according to the present invention refers to a cardiovascular disorder or cardiovascular event such as for example ischemic heart disease, carotid and intracerebral artery disease, peripheral arteria l d isease, aortic aneurism and the l ike , and any 
<!-- EPO <DP n="15"/>-->
 combinations thereof. Preferably CVD refers to myocardial infarction, stroke, dementia, critical limb ischemia, aortic aneurism and any combinations thereof, more preferably to myocardial infarction, stroke, vascular dementia and any combinations thereof. </p><p id="p0033" num="0033">As used herein, the term "subtherapeutic daily dose" in the context of the at least one renin-angiotensin-aldosterone system inhibitor relates to a dose, which does not substantially lower the blood pressure. Preferably, the systolic blood pressure is not lowered by more than 15%, preferably not more than 10% by a subtherapeutic dose according to the present invention. In another preferred embodiment, the diastolic blood pressure is not lowered by more than 15%, preferably not more than 10%. </p><p id="p0034" num="0034">The recommended daily therapeutic dose for a renin-angiotensin-aldosterone system inhibitor is typically in the range of 20 mg to 320 mg. For example for the active Valsartan the recommended therapeutic daily dose is in the range of 40 mg to 320 mg. For Losartan the recommended therapeutic daily dose is in the range of 25 mg to 100 mg. The term "pharmaceutically acceptable salts" includes any and all non-toxic, salts of the disclosed compounds. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts and basic salt. The pharmaceutically acceptable salts include, but are not limited to metal salts, such as sodium salt, potassium salt, cesium salt, and the like; alkaline earth metals, such as calcium salt, magnesium salt and the like, organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and the like, inorganic acid salts, such as hydrochloride, hydrobromide, phosphate, sulphate and the like, organic acid salts such as citrate, lactate, tartrate, m aleate, fum arate, m andelate , acetate , d ich loroacetate, 
<!-- EPO <DP n="16"/>-->
 trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like, and amino acid salts such as arginate, glutamate, and the like. Acid addition salts can be formed by mixing a solution of the particular compound of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, and the like. Basic salts can be formed by mixing a solution of the particular compound of the present invention and a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like. </p><p id="p0035" num="0035">The term "daily dose" of the pharmaceutically active ingredient(s) corresponds to the total amount of said active/the actives that is/are administered to a subject per day. The daily dose can be administered in any suitable frequency such as in a once-a-day dosage or alternatively in a divided dosage, e.g. twice-a-day dosage or dosages which have to be administered 3 or 4 times a day. The term "residual improvement" refers to a change in the improvement of a parameter as measured after a certain time period (e.g. a rest period) in relation to the improvement achieved after a treatment period. The residual improvement after said time period is given as a percentage of the initial improvement (measured e.g. after determination of the treatment). As an exam ple, the FM D at beginn ing of the treatment was 1 % . The FM D measured after a treatment period was 4 % (improvement 300%) and the FMD measured after a rest period following the treatment period was 3%, leading to a residual improvement of 67%. 
<!-- EPO <DP n="17"/>-->
 The term "substantially", if not defined otherwise in the context it is used, means that the value following the term may diviate ±10%, preferably ±5%. </p><p id="p0036" num="0036">The term "treatment period" as used herein is defined as the time period in which a subject is adm inistered the daily dosis of the pharmaceutical composition according to the present invention. </p><p id="p0037" num="0037">The term "rest period" as used herein is defined as the time period in which a subject is not administered the pharmaceutical composition of the present invention. </p><p id="p0038" num="0038">Figures </p><p id="p0039" num="0039">Figure 1 : Changes expressed in percentage of A) flow mediated dilation (FMD), B) β-stiffness of carotid artery and pulse wave velocity (PVW) and in placebo and treated group after 1 month (30 days) of treatment (Example 1 ) </p><p id="p0040" num="0040">Figure 2: Beneficial arterial characteristics (expressed in percentage of the effect achieved after 1 month (30 days) of treatment) that still persist 5, 7 and 8 months after discontinuation of treatment according to Example 1 (Example 2) </p><p id="p0041" num="0041">Figure 3: Effect of the treatment according to Example 1 and Example 2 on "biological" arterial ageing (Example 3) </p><p id="p0042" num="0042">Figure 4: Values of flow mediated dilation (FMD), β-stiffness of carotid artery and pulse wave velocity (PVW) in placebo and treated group after 1 month (30 days) of treatment (Example 4) 
<!-- EPO <DP n="18"/>-->
 Figure 5: Beneficial arterial characteristics (expressed in percentage of the effect achieved after 1 month (30 days) of treatment) that still persist 3, 8 and 10 months after discontinuation of treatment according to Example 4 (Example 5) </p><p id="p0043" num="0043">Figure 6: Changes expressed in percentage of flow mediated dilation (FMD), β-stiffness of carotid artery and pulse wave velocity (PVW) of treated group after 1 month (30 days) (1 . intervention) and after a 2. intervention (treatment for 1 month - 30 days) after a 12-months rest period. Subjects of the 2. </p><p id="p0044" num="0044">intervention were the same participants as in Example 1 . </p><p id="p0045" num="0045">Detailed description of invention </p><p id="p0046" num="0046">One embodiment of the present invention is directed to a pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0047" num="0047">In another embodiment the present invention is directed to a pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose, for use in decreasing the occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0048" num="0048">Without being bound to theory, the inventor believes that the prevention, reduction or reversal of arterial ageing, as evidenced for example by the reduction achieved by the pharmaceutical composition according to the present invention in the PVW and the β-stiffness will lead to a decrease in occurrence of cardiovascular disorders in apparently healthy subjects. The decrease in occurrence of the cardiovascular disorder may be indicated e.g. by the difference in the 10 year risk factor for CHD diseases (Framingham 
<!-- EPO <DP n="19"/>-->
 Heart Study) calculated for the chronological age before the beginning of the treatment and the one calculated after the treatment using the calculated biological age. The at least one renin-angiotensin-a l doste rone i n h i b itor of th e pharmaceutical composition of the present invention may be selected from the group consisting of renin inhibitor, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist and combinations thereof. In a preferred embodiment of the present invention the at least one renin- angiotensin-aldosterone system inhibitor is an angiotensin II receptor antagonist. </p><p id="p0049" num="0049">Preferrably the angiotensin II receptor antagonist is selected from the group consisting of azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters and any combinations thereof. More preferably, the angiotensin II receptor antagonist is selected from the group consisting of azilsartan, losartan, olmesartan, candesartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters, and combinations thereof, even more preferably the angiotensin II receptor antagonist is selected from the group consisting of azilsartan, losartan, candesartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters, and combinations thereof, even more preferably the angiotensin II receptor antagonist is selected from the group consisting of losartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters, and combinations thereof, or losartan, valsartan, and any pharmaceutically acceptable salts or esters, and combinations thereof. 
<!-- EPO <DP n="20"/>-->
 In a particularity preferred embodiment of the present invention the angiotensin II receptor antagonist is valsartan or any pharmaceutically acceptable salt thereof, preferably valsartan. In a further particularily preferred embodiment of the present invention the angiotensin II receptor antagonist is losartan or any pharmaceutically acceptable salt thereof, preferably losartan potassium. </p><p id="p0050" num="0050">In one embodiment of the present invention, the subtherapeutic daily dose of the renin-angiotensin-aldosterone system inhibitor does not substantially change the systolic blood pressure in a subject. </p><p id="p0051" num="0051">In one embodiment of the present invention, the subtherapeutic daily dose of the renin-angiotensin-aldosterone system inhibitor does not substantially change the diastolic blood pressure in a subject. </p><p id="p0052" num="0052">In one embodiment of the present invention, the subtherapeutic daily dose of the renin-angiotensin-aldosterone system inhibitor does not lower the systolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 6%, most preferably more than 4%. </p><p id="p0053" num="0053">In one embodiment of the present invention, the subtherapeutic daily dose of the renin-angiotensin-aldosterone system inhibitor does not lower the systolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 6% , most preferably more than 4%, when administered for at least 10 days, preferably at least 14 days, more preferably at least 1 month. </p><p id="p0054" num="0054">In yet another embodiment of the present invention, the subtherapeutic daily dose of the renin-angiotensin-aldosterone system inhibitor does not lower the 
<!-- EPO <DP n="21"/>-->
 diastolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 8%, most preferably more than 5%. </p><p id="p0055" num="0055">In yet another embodiment of the present invention, the subtherapeutic daily dose of the renin-angiotensin-aldosterone system inhibitor does not lower the diastolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 8%, most preferably more than 5%, when administered for at least 10 days, preferably at least 14 days, more preferably at least 1 month. </p><p id="p0056" num="0056">In yet another embodiment of the present invention the subtherapeutic daily dose of the renin-angiotensin-aldosterone inhibitor is between 1 and 50%, preferably between 1 and 25% of the daily recommended therapeutic dose for the primary medical indication of said active. </p><p id="p0057" num="0057">The subtherapeutic daily dose of the renin-angiotensin-aldosterone inhibitor is preferably between 1 and 75 mg, between 1 and 60 mg, between 1 and 50 mg, between 1 and 45 mg, between 1 and 40 mg, and/or between 1 and 25 mg. In another embodiment the daily dose of the renin-angiotensin- aldosterone inhibitor is selected from 10, 15, 20, 25, or 30 mg. </p><p id="p0058" num="0058">In one embodiment of the present invention the renin-angiotensin- aldosterone is valsartan or any pharmaceutically acceptable salts or esters thereof, and the subtherapeutic daily dose is between 1 and 75 mg, preferably between 1 and 60 mg, more preferably between 1 and 50 mg, still more preferably between 1 to 40 mg, most preferably between 10 to 30 mg, particularly preferably 20 mg. </p><p id="p0059" num="0059">In one embodiment of the present invention the renin-angiotensin- aldosterone is telmisartan or any pharmaceutically acceptable salts or esters 
<!-- EPO <DP n="22"/>-->
 thereof, and the subtherapeutical dose thereof is between 1 to 40 mg, preferably between 1 to 20 mg, most preferably 20 mg. </p><p id="p0060" num="0060">In one embodiment of the present invention the renin-angiotensin- aldosterone is losartan or any pharmaceutically acceptable salts or esters thereof, and the subtherapeutical dose thereof is between 1 to 40 mg, preferably between 1 to 30 mg, more preferably 20 mg and most preferably 12,5 mg. The present invention is directed to a pharmaceutical compostion comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose for use in the prevention, reduction or reversal of arterial aging in apparently healthy subjects. An apparently healthy subject having a low cardiovascular risk exhibits a Framingham Risk Score for a CHD (10-year risk) of 10% or less, preferably 8% or less, more preferably 5% or less as defined above. </p><p id="p0061" num="0061">Preferably the apparently healthy subject does not have a (manifested) cardiovascular disorder. Preferably, the apparently healthy subject does not have a (manifested) cardiovascular disorder and in addition does not have disorders which importantly influence the functional capacity of different tissues/organs or the whole body. The term cardiovascular disorder (CVD) according to the present invention refers to a cardiovascular disorder or cardiovascular event such as for example ischemic heart disease, carotid and intracerebral artery disease, peripheral arterial disease, aortic aneurism and the like, and any combinations thereof. Preferably CVD refers to myocardial infarction, stroke, dementia, critical limb ischem ia, aortic aneurism and any combinations 
<!-- EPO <DP n="23"/>-->
 thereof, more preferably to myocardial infarction, stroke, vascular dementia and any combinations thereof. </p><p id="p0062" num="0062">In one embodiment, the apparently healthy subject is a mammal, preferably a human subject. </p><p id="p0063" num="0063">In one aspect of the present invention, the pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose is useful for treatment for a period for at least one week, at least two weeks, preferably between 2 weeks and 3 months, more preferably between 2 weeks and 2 months, and more preferably between 2 weeks and 1 month, and most preferably after treatment for 1 month (e.g. 30 or 31 days). In one embodiment the flow-mediated dilatation of brachial artery (FMD) after a period of treatment, preferably after 1 month of treatment, compared to the beginning of the treatment is increased. In a preferred aspect of this embodiment, the FMD increases by at least 25%, preferably at least 50%, more preferably at least 100%, still more preferably at least 125%, most preferably at least 150%, particularly preferably 156.0 % after a treatment period, preferably 1 month of treatment, compared to the beginning of the treatment. </p><p id="p0064" num="0064">In another embodiment of the present invention, a decrease of the pulse- wave velocity (PWV) after a period of treatment, preferably after 1 month of treatment, compared to the beginning of the treatment is achieved. In a preferred aspect of this embodiment the PWV decreases by at least 1 %, preferably at least 3%, more preferably at least 5%, most preferably at least 7%, particularly preferably 7.2 % after a treatment period, preferably 1 month of treatment compared to the beginning of the treatment. 
<!-- EPO <DP n="24"/>-->
 In yet another embodiment of the present invention, the β-stiffness of carotid artery after a period of treatment, preferably after 1 month of treatment, com pared to the beginning of the treatment is decreased. In a preferred aspect of this em bod im ent the β-stiffness decreases by at least 3% , preferably at least 5%, more preferably at least 10%, and most preferably at least 13%%, particularly preferably 13.7 % after a treatment period, preferably 1 month of treatment, compared to the beginning of the treatment. The effect on arterial aging may be determ ined by measuring the difference in the parameters of the pulse-wave velocity (PVW) and the β-stiffness of carotid artery after a treatment period, preferably 1 month of treatment compared to the beginning of the treatment. The effect achieved by a pharm aceutically active substance is usually determined by the presence of a therapeutically effective concentration of said active in the blood. Therefore, the half-life time (t-i<sub>/2</sub>) in the blood plasma is an important factor which influences the period of time for which efficacy of a dosis regimen may be observed. For example the half-life time for valsartan is about 6.0 hours and for losartan about 1 .5-2 hours, Therefore, it can be expected that a pharmaceutical effect can only be maintained as long as the pharmaceutically active substance is administered on a regular basis, e.g. on a daily basis, twice-a-days-basis, or the like. This is also reflected by the treatment schedule of the primary indications of the renin-angiotensin- aldosterone system inhibitors. </p><p id="p0065" num="0065">It has surprisingly been found by the inventor of the present invention that the use of the pharmaceutical composition according to the present invention comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose allows for an exceptionally long term persistence of 
<!-- EPO <DP n="25"/>-->
 the improvements achieved for the arterial characteristics after discontinuation of the treatment resulting in long term improvement of arterial wall properties such as the arterial ageing. This improvement is reflected for example by the residual of the improvement compared to the beginning of the treatment. The phenomenon is described in the present invention by the term "rest period". In the art also the term "activity during drug-free period" is used. The two terms "rest period" and "activity during drug-free period" are used interchangeably. In one embodiment of the present invention the reduction or reversal of arterial aging after a period of treatment persists in a substantial amount the for at least 1 month, preferably at least 3 months, more preferably at least 5 months, still more preferably at least 7 months, 8 months, most preferably at least 10 months, particularly preferably for approximately at least 12 months after discontinuation of the treatment. </p><p id="p0066" num="0066">In one aspect of this embodiment, after discontinuation of the treatment for at least 1 months the residual improvement of the PVW is at least 5%, preferably at least 10%, more preferably at least 15%, still more preferably at least 20%, most preferably at least 25% based on the decrease of the PVW after a period of treatment. In one aspect of this embodiment, after discontinuation of the treatment for at least 3 months the residual improvement of the PVW is at least 5% , preferably at least 1 0% , more preferably at least 15%, still more preferably at least 20%, most preferably at least 25% based on the decrease of the PVW after a period of treatment. In one aspect of this embodiment, after discontinuation of the treatment for at least 5 months the residual improvement of the PVW is at least 5%, preferably at least 10%, more preferably at least 15%, still more preferably at least 20%, most preferably at least 25% based on the decrease of the PVW after a period of treatment. In a preferred aspect of this embodiment after 
<!-- EPO <DP n="26"/>-->
 discontinuation of the treatment for at least 7 months the residual improvement of the PWV is at least 2%, preferably at least 4%, more preferably at least 6%, most preferably at least 8%, particularly preferably 9.9% based on the decrease of the PWV after a period of treatment. In a preferred aspect of this embodiment after discontinuation of the treatment for at least 8 months the residual improvement of the PWV is at least 0.5%, preferably at least 1 %, more preferably at least 1 .5%, most preferably at least 2%, even more preferably 2.5% based on the decrease of the PWV after a period of treatment. </p><p id="p0067" num="0067">In another aspect of the invention, after discontinuation of the treatment for at least 1 months the residual improvement of the β-stiffness is at least 5%, preferably at least 10%, more preferably at least 15%, and most preferably at least 20% based on the decrease of the β-stiffness after a period of treatment. In another aspect of the invention, after discontinuation of the treatment for at least 3 months the residual improvement of the β-stiffness is at least 5%, preferably at least 10%, more preferably at least 15%, and most preferably at least 20% based on the decrease of the β-stiffness after a period of treatment. In another aspect of the invention, after discontinuation of the treatment for at least 5 months the residual im provement of the β- stiffness is at least 5%, preferably at least 10%, more preferably at least 1 5%, and most preferably at least 20% based on the decrease of the β- stiffness after a period of treatment. I n another preferred aspect of this embodiment after discontinuation of the treatment for at least 7 months the residual improvement of the β-stiffness is at least 1 %, preferably at least 3%, more preferably at least 5%, and most preferably at least 8%, particularly preferably 9.9% based on the decrease of the β-stiffness after a period of treatment. In a preferred aspect of this embodiment after discontinuation of the treatment for at least 8 months the residual im provement of the β- stiffness is at least 0.5%, preferably at least 1 %, more preferably at least 
<!-- EPO <DP n="27"/>-->
 1 .5%, and most preferably at least 2% based on the decrease of the β- stiffness after a period of treatment. </p><p id="p0068" num="0068">In one aspect of this embodiment, after discontinuation of the treatment for at least 1 months the residual im provement of the FM D is at least 1 5% , preferably at least 25%, more preferably at least 35%, most preferably at least 45% based on the increase of the FMD after a period of treatment. In one aspect of this embodiment, after discontinuation of the treatment for at least 3 months the residual improvement of the FMD is at least 15%, preferably at least 25%, more preferably at least 35%, most preferably at least 45% based on the increase of the FMD after a period of treatment. In one aspect of this embodiment, after discontinuation of the treatment for at least 5 months the residual improvement of the FMD is at least 15%, preferably at least 25%, more preferably at least 35%, most preferably at least 45% based on the increase of the FMD after a period of treatment. In another preferred aspect of this embodiment after discontinuation of the treatment for at least 7 months the residual improvement of the FMD is at least 1 0% , preferably at least 1 5% , more preferably at least 20% , most preferably at least 25%, even more preferably at least 30%, particularly preferably 30.4% based on the increase of the FM D after a period of treatment. In a preferred aspect of this embodiment after discontinuation of the treatment for at least 8 months the residual improvement of the FMD is at least 1 %, preferably at least 3%, more preferably at least 5%, most preferably at least 6% based on the increase of the FMD after a period of treatment. </p><p id="p0069" num="0069">In one embodiment of the present invention, the pharmaceutical composition according to the present invention for use in the prevention, reduction or reversal of arterial aging is applied in a repeated intervention cycle comprising at least one treatment-period followed by at least one rest-period. 
<!-- EPO <DP n="28"/>-->
 The intervention cycle is preferably repeated at least once, more preferably 2, 3, 4 or 5 times. </p><p id="p0070" num="0070">The treatment-period may last at least one week, at least two weeks, preferably between 2 weeks to 3 months, more preferably between 2 weeks and 2 months, still more preferably between 2 weeks and 1 month (e.g. 30 or 31 days). </p><p id="p0071" num="0071">The rest-period may be at least 1 day, preferably at least 1 week, more preferably at least 1 month, more preferably at least 3 months, still more preferably at least 4 months, more preferably at least 6 months, most preferably at least 8 months, particularly preferably approximately 10 or 12 months. The pharmaceutical composition according the present invention comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose may comprise one or more further active agents, preferably selected from the group consisting of an anti-inflammatory agent, an antioxidant, and combinations thereof. </p><p id="p0072" num="0072">The anti-inflammatory agents and/or the antioxidants may be selected from the group defined below. </p><p id="p0073" num="0073">In one embodiment of the present invention, the pharmaceutical composition may further comprise an anti-inflammatory agent and an antioxidant, with the proviso that the pharmaceutical composition is not vitamin C and/or vitamin E. </p><p id="p0074" num="0074">In one embodiment of the present invention, the pharmaceutical composition does not comprise vitamin C and/or vitamin E. 
<!-- EPO <DP n="29"/>-->
 In one embodiment of the present invention, the pharmaceutical composition does not comprise fluvastatin or a pharmaceutically acceptable salt thereof. In another embodiment of the present invention, the pharmaceutical composition may further comprise an anti-inflammatory agent, but not comprising an antioxidant. </p><p id="p0075" num="0075">In yet another embodiment of the present invention the pharmaceutical composition may comprise an antioxidant and an anti-inflammatory agent, wherein the anti-inflammatory agent is not acetylsalicylic acid. </p><p id="p0076" num="0076">In yet another embodiment of the present invention, the pharmaceutical composition may further comprise an antioxidant, but not comprising an anti- inflammatory agent. </p><p id="p0077" num="0077">In yet another embodiment of the present invention, the pharmaceutical composition may further comprise an anti-inflammatory agent and/or an antioxidant. In a preferred embodiment the anti-inflammatory agent is selected from the group consisting of acetylsalicylic acid and resveratrol. In another preferred embodiment the antioxidant is coenzyme Q10 or any analogue thereof. In a preferred embodiment of the present invention the anti-inflammatory agent is acetylsalicylic and the antioxidant is coenzyme Q10. </p><p id="p0078" num="0078">In case acetylsalicylic acid is present in the pharmaceutical composition according to the present invention it is present in an amount, which corresponds to a weight ratio of acetylsalicylic acid and renin-angiotensin- aldosterone system inhibitor of from 15: 1 to 1 :2, preferably 10: 1 to 2.5: 1 , more preferably 6:1 to 4: 1 , most preferably 5:1 . In another embodiment of the 
<!-- EPO <DP n="30"/>-->
 present invention, the pharmaceutical composition comprises acetylsalicylic acid in a daily dose of between 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg. I n case coenzyme Q 1 0 is present in the pharm aceutical com position according to the present invention it is present in an amount which corresponds to a weight ratio of acetylsalicylic acid and renin-angiotensin- aldosterone system inhibitor of from 15: 1 to 1 :2, preferably 10: 1 to 2.5: 1 , more preferably 6: 1 to 4: 1 , most preferably 5: 1 . In another embodiment of the present invention the pharmaceutical composition comprises coenzyme Q10 in a daily dose of 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg. </p><p id="p0079" num="0079">In a preferred embodiment of the present invention the pharmaceutical composition comprises valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40 mg, preferably between 10 to 30 mg, most preferably 20 mg, and acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form. In a preferred embodiment of the present invention the pharmaceutical composition comprises valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40 mg, preferably between 10 to 30 mg, most preferably 20 mg, and acetylsalicylic acid in a daily dose between 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg and/or coenzyme Q10 1 to 200 mg, preferably 50 to 1 50 mg, most preferably 1 00 mg. </p><p id="p0080" num="0080">In one embodiment, the present invention relates to a pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other 
<!-- EPO <DP n="31"/>-->
 active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein one intervention-cycle is repeated at least 3, 4 or 5 times. One intervention-cycle may consist of one treatment-period lasting between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month and one rest-period lasting approximately 12 months, preferably between 6 and 12 months. In another embodiment, the present invention relates to the pharmaceutical composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form. In another embodiment, the present invention relates to the pharmaceutical composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0081" num="0081">In another embodiment, the present invention is the pharmaceutical composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. 
<!-- EPO <DP n="32"/>-->
 Further embodiments of the invention relate to the pharmaceutical composition according to present invention further comprising one or more pharmaceutically acceptable excipient. One of the embodiment of the present invention is the pharmaceutical composition comprising at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0082" num="0082">The inventors of the present application surprisingly found out that the pharmaceutical combination composition according to the present invention provides beneficial effect by substantially improving both functional characteristics such as for example endothelial function measured by flow- mediated dilatation of brachial artery (FMD) and morphological characteristics such as for example stiffness and elasticity of arteries measured by pulse-wave velocity (PVW) and β-stiffness of carotid artery. It is important to emphasize the similarity between the terms morphological or structural which are used to describe the same characteristics by different authors but basically disclosed the same characteristics of arterial wall. All three above mentioned methods are standard and generally widely accepted methods for estimation of functional and morphological characteristics of arteries. It is important to emphasize that there is a similarity between the terms morphological or structural which are used to describe the same characteristics by d ifferent authors but basically d isclose the same characteristics of arterial wall. All three above mentioned methods FMD, PVW and β-stiffness are standard in the art and generally widely accepted methods for estimation of functional or morphological characteristics of arteries. When administering the pharmaceutical combination composition 
<!-- EPO <DP n="33"/>-->
 according to the present invention the significant and unexpected improvement in all above mentioned characteristics are observed. Furthermore, by using age-related normogram obtained on large sample of apparently healthy subjects -who have a low cardiovascular risk as defined above - the estimation of "biological" arterial age can be determined. The inventors of the present application surprisingly found out that there is a significant and unexpected decrease of "biological" arterial age by applying the pharmaceutical compositions of the present invention after treatment. The term renin-angiotensin-aldosterone system (RAAS) inhibitor as used in the present invention can include renin inhibitor, angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor antagonist and any combinations thereof. The renin inhibitor can be aliskiren. </p><p id="p0083" num="0083">The term ACE inhibitor as used in the present invention can include, but is not limited to, benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, trandolapril, moexipril, quinapril, ramipril and any pharmaceutically acceptable salts or esters thereof. Preferably ACE inhibitor can be selected from the group consisting of, but not limited to, perindopril, lisinopril, enalapril, moexipril, ramipril and any pharmaceutically acceptable salts or esters thereof, more preferably it can be selected from the group consisting of, but not limited to, perindopril and ramipril and any pharmaceutically acceptable salts or esters thereof. </p><p id="p0084" num="0084">The term angiotensin II receptor antagonist as used in the present invention can include, but is not limited to, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof. Preferably angiotensin II 
<!-- EPO <DP n="34"/>-->
 receptor antagonist can be selected from the group consisting of, but not limited to, azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably it can be selected from the group consisting of, but not limited to, losartan, telm isartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably angiotensin I I receptor antagonist is valsartan and telm isartan and any pharmaceutically acceptable salts or esters thereof. Moreover, the term angiotensin II receptor antagonist as used in the present invention can further include one or more combination with other active substance such as for example combination with diuretic, preferably thiazide diuretic and more preferably hydrochlorothiazide, combination with calcium channel blockers and any pharmaceutically acceptable salts thereof, such as for example dihydropiridine calcium channel blockers that can be selected from the group consisting of, but not lim ited to, am lodipine, felodipine, lacidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine and any pharmaceutically acceptable salts thereof and any combinations thereof. </p><p id="p0085" num="0085">Moreover, the term RAAS inhibitor as used in the present invention can further include one or more combination with other active substance such as for example, but not limited to, combination with diuretic, such as for example thiazide such as for example chlorothiazide, chlorthalidone, hydrochlorothiazide, hydroflumethiazide, indapamide, methyclothiazide, metolazone, polythiazide, preferably hydrochlorothiazide and indapamide; loop diuretic such as for example bumetanide, ethacrynic acid, furosemide, torsemide, preferably furosemide and torsemide; K+-sparing diuretic such as for example amioloride, eplerenone, spironolactone, triamterene, preferably eplerenone and spironolactone; and Ca-inhibitors such as for example 
<!-- EPO <DP n="35"/>-->
 acetazolamide, dichlorphenamide, methazolamide; more preferably hydrochlorothiazide; combination with calcium channel blockers such as for example dihydropiridine calcium channel blockers that can be selected from the group consisting of, but not limited to, amlodipine, aranidipine, azelnidipine, barnidipine, benidipine, felodipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, pranidipine, preferably amlodipine, and any pharmaceutically acceptable salts or esters thereof and any combinations thereof. Preferably the term RAAS inhibitor as used in the present invention means angiotensin II receptor antagonist, more preferably valsartan or telmisartan or any pharmaceutically acceptable salts or esters thereof. </p><p id="p0086" num="0086">Therefore, another object of the present invention is the pharmaceutical combination composition comprising at least one renin-angiotensin- aldosterone system inhibitor selected from the group consisting of, but not limited to, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0087" num="0087">Another object of the present invention is the pharmaceutical combination composition comprising at least one angiotensin I I receptor antagonist, selected from the group consisting of, but not limited to, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably 
<!-- EPO <DP n="36"/>-->
 losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0088" num="0088">Still another object of the present invention is the pharmaceutical com bination com position com prising valsartan or any pharmaceutical ly acceptable salts thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0089" num="0089">Still another object of the present invention is the pharmaceutical combination composition comprising telmisartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. The term anti-inflammatory agent as used in the present invention can include, but is not limited to, classic non-steroidal antiinflammatory agents (NSAIDS), such as for example acetylsalicyclic acid, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen , nabum etone, acetam inophen and any pharm aceutica l ly 
<!-- EPO <DP n="37"/>-->
 acceptable salts thereof; COX-2 inhibitors, such as for example nimesulide, flosulid, celecoxib, rofecoxib, parecoxib sodium, valdecoxib, etoricoxib, etodolac, meloxicam and any pharmaceutically acceptable salts thereof; glucocorticoids, such as for example hydrocortisone, cortisone, prednisone, predn isolone , m ethyl predn isolone , m epredn isone , triam cinolone , paramethasone, fluprednisolone, betamethasone, dexamethasone, fludrocortisone, desoxycorticosterone, rapamycin and any pharmaceutically acceptable salts thereof; resveratrol and any analogues of these agents. Preferably anti-inflammatory agent can be selected from the group consisting of, but not limited to, acetylsalicyclic acid, ketoprofen, ibuprofen, naproxen, celecoxib, rofecoxib, meloxicam, hydrocortisone, cortisone, prednisone, prednisolone, betamethasone, dexamethasone, resveratrol and any pharmaceutically acceptable salts thereof and/or any analogues, more preferably acetylsalicyclic acid, ibuprofen, celecoxib, hydrocortisone, dexamethasone, resveratrol and any pharmaceutically acceptable salts thereof and/or any analogues of these agents, and even more preferably acetylsalicyclic acid and resveratrol and any pharmaceutically acceptable salts thereof and/or any analogues thereof. In a preferred embodiment of the invention the anti-inflammatory agent is present in the pharmaceutical combination composition in the efficient amount to reduce inflammation. </p><p id="p0090" num="0090">The term antioxidant as used in the present invention can include, but is not lim ited to, butylatedhydroxyanisole, butylatedhydroxytoluene, malic acid, ascorbylpalmitate, sodium ascorbate, sodium metabisulphite, propyl gallate, beta-carotene, ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbic acid-2 -glycoside, ascorbylpalmitate, ascorbyl stearate, a-lipoic acid, glutathione, coenzyme Q10, tocopherol, tocopherol acetate, retinol, retinol palm itate, genistein, quercetin, epigallocatechin, 
<!-- EPO <DP n="38"/>-->
 epigallocatechingallate, gallocatechingallate, sylibin, diosmetin, kaempferol, epicatechin, galangin, indolic acid, γ-linolenic acid, linoleic acid, chlorogenic acid, tocotrienol, astaxanthin, and any pharmaceutically acceptable salts thereof and/or any analogues thereof. Preferably, the antioxidant can be selected from the group consisting of, but not lim ited to, ascorbic acid, sodium ascorbyl phosphate, coenzyme Q10, magnesium ascorbyl phosphate, ascorbic acid-2-glycoside, butylatedhydroxyanisole, chlorogenic acid , epigal locatech i ngal late, indol ic acid , a-l i p o i c a c i d a n d a n y pharmaceutically acceptable salts thereof and/or any analogues thereof, more preferably ascorbic acid, sodium ascorbyl phosphate, coenzyme Q10, magnesium ascorbyl phosphate, ascorbic acid-2-glycoside, butylatedhydroxyanisole and any pharmaceutically acceptable salts thereof and/or any analogues thereof and even more preferably coenzyme Q10 and any pharmaceutically acceptable salts thereof and/or any analogue thereof. </p><p id="p0091" num="0091">In a preferred embodiment of the invention the antioxidant is present in the pharmaceutical combination composition in the efficient amount to inhibit oxidation. According to the present invention the term subtherapeutic daily dose relates to the dose that does not substantially lower the blood pressure, as defined above therefore the beneficial effects at this dose are attributed solely/purely to the pleiotropic effects of renin-angiotensin-aldosterone system inhibitor. Preferably, the subtherapeutic daily dose is between 1 and 50%, more preferably between 1 and 25% of daily recommended therapeutic dose for particular active substance. A subtherapeutic daily dose does not produce side-effects which are important limitation of therapeutic dosages particularly for long term usage during which known and still unknown complications or side-effects could occur. It is well known that side-effects are related to the dose of the used drug being more frequent at higher dosages. 
<!-- EPO <DP n="39"/>-->
 According to the state of the art the starting recommended daily dose for valsartan is 80mg and the starting recommended daily dose for telmisartan is 40mg, therefore the term subtherapeutic daily dose according to the present invention means between 1 and 40mg if valsartan or any pharmaceutically acceptable salts or esters thereof is used as RAAS inhibitor and between 1 and 20mg if telmisartan or any pharmaceutically acceptable salts or esters thereof is used as RAAS inhibitor. </p><p id="p0092" num="0092">In a preferred embodiment, the present invention relates to the pharmaceutical combination composition comprising at least one renin- angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein the subtherapeutic daily dose is between 1 and 50%, preferably between 1 and 25% of daily recommended therapeutic dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0093" num="0093">Another object of the present invention is the pharmaceutical combination composition comprising at least renin-angiotensin-aldosterone system inhibitor selected from the group consisting of, but not limited to, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein the subtherapeutic daily dose is between 1 and 50%, 
<!-- EPO <DP n="40"/>-->
 preferably between 1 and 25% of daily recommended therapeutic dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0094" num="0094">Another object of the present invention is the pharmaceutical combination composition comprising at least one angiotensin II receptor antagonist, selected from the group consisting of, but not limited to, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein the subtherapeutic daily dose is between 1 and 50%, preferably between 1 and 25% of daily recommended therapeutic dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0095" num="0095">Another object of the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally at least one other active agent selected from the group consisting of an anti-inflammatory 
<!-- EPO <DP n="41"/>-->
 agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0096" num="0096">Another object of the present invention is the pharmaceutical combination composition comprising telmisartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 20mg and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0097" num="0097">The term apparently healthy subject according to the present invention relates to a subject having a low cardiovascular risk as defined above. </p><p id="p0098" num="0098">Furthermore, it was unexpectedly found out that the effect of prevention, reduction or reversal of arterial ageing in apparently healthy subjects when using the pharmaceutical combination composition according to the present invention is surprisingly achieved after treatment defined as a treatment- period, that can last for at least 1 week, at least 2 weeks, between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month. </p><p id="p0099" num="0099">Therefore, in another preferred embodiment, the present invention relates to a pharmaceutical combination composition comprising at least one renin- angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects in a treatment-period lasting at least 1 week, at least two weeks, between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month. 
<!-- EPO <DP n="42"/>-->
 Another preferred embodiment of the present invention relates to a pharmaceutical combination composition comprising at least one renin- angiotensin-aldosterone system inhibitor selected from the group consisting of, but not limited to, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflam matory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects in a treatment-period lasting between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month. </p><p id="p0100" num="0100">Another preferred embodiment of the present invention relates to a pharmaceutical combination composition comprising at least one angiotensin II receptor antagonist, selected from the group consisting of, but not limited to, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects in a treatment-period lasting between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month. 
<!-- EPO <DP n="43"/>-->
 Another preferred embodiment of the present invention relates to a pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects in a treatment-period lasting between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month. </p><p id="p0101" num="0101">Another preferred embodiment of the present invention relates to a pharmaceutical combination composition comprising telmisartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 20mg and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects in a treatment-period lasting between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month. </p><p id="p0102" num="0102">The above mentioned objects of the present invention were determined in a double-blind study wherein 40 apparently healthy subjects were randomly assigned to treatment (valsartan 20 mg daily, 1 month - 30 days) or placebo. The main functional and morphological characteristics of arteries were tested by measurement of flow-mediated dilatation of brachial artery (FMD), pulse- wave velocity (PVW) and β-stiffness of carotid artery once at baseline and after 30 days. All parameters of arterial function were significantly improved after 30 days of treatment: a) FMD increased by 156.0 % (p&lt;0.001 ), 
<!-- EPO <DP n="44"/>-->
 b) PVW decreased by 7.2 % (p&lt;0.01 ) and </p><p id="p0103" num="0103">c) β-stiffness decreased by 13.7 % (p&lt;0.01 ). </p><p id="p0104" num="0104">Said beneficial arterial characteristics were not accompanied by any changes in blood pressure. </p><p id="p0105" num="0105">Furthermore, the inventors observed substantial long term persistence of beneficial arterial characteristics. Thus, it was unexpectedly found out that the beneficial effect on arterial ageing when administering the pharmaceutical com bination com position according to the present invention surprisingly persisted in an substantial amount even approximately 1 month, 3, 4, 5, 6, 7, 8 or 12 months, preferably between 6 and 12 months, after discontinuation of treatm ent. The period without any treatm ent according to the present invention and wherein the beneficial arterial characteristics are still present is named as the rest- period. One of the aims of the rest-period is to prevent the occurrence of 'resistance' to therapy leading to decreased efficacy after certain time. If any inhibitory process is induced by treatment which seems to be logical it would be dim inished during the rest period. That means that repeating of treatment would not result in a decreased efficacy but rather in a sim ilar or even higher efficacy. Based on that assumption one could predict that a very long term of use (decades) could be possible without significantly lost efficacy of treatment. Another important aims of rest-period are higher compliance of patients and fewer side effects. Therefore, still another embodiment of the present invention relates to the pharmaceutical composition comprising at least one renin-angiotensin- aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy 
<!-- EPO <DP n="45"/>-->
 subjects having at least one treatment period and at least one rest period characterised that the rest-period is approximately 1 month, 3, 4, 5, 6, 7, 8 or 12 months, preferably between 6 and 12 months. Another object of the present invention relates to the pharmaceutical combination composition comprising at least one angiotensin II receptor antagonist, selected from the group consisting of, but not limited to, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telm isartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects characterised in that the rest-period is approximately 1 month, 3, 4, 5, 6, 7, 8 or 12 months, preferably between 6 and 12 months. </p><p id="p0106" num="0106">Another object of the present invention relates to the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects characterised that the rest-period is approximately 1 month, 3, 4, 5, 6, 7, 8 or 12 months, preferably between 6 and 12 months. 
<!-- EPO <DP n="46"/>-->
 Another object of the present invention relates to the pharmaceutical combination composition comprising telmisartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 20mg and optionally at least one other active agent selected from the group consisting of an anti- inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects characterised that the rest-period is approximately 1 month, 3, 4, 5, 6, 7, 8 or 12 months, preferably between 6 and 12 months. In the extension of the above mentioned study the presence of beneficial arterial characteristics was measured after discontinuation of treatment. Surprisingly it was found out that the beneficial arterial characteristics measured in the same observed group of subjects were still present in substantial amounts even after up to 12 months. For example, after 7 months of discontinuation the beneficial arterial characteristics were still present at the following percentage of initial improvement achieved after 1 month (30 days) of treatment disclosed above: a) FMD still increased by 30.4 %, </p><p id="p0107" num="0107">b) PVW still decreased by 9.9% and </p><p id="p0108" num="0108">c) β-stiffness still decreased by 9.2 %. </p><p id="p0109" num="0109">In another preferred embodiment, the the present invention relates to a specific, original approach for implementation of the above mentioned obtained beneficial arterial characteristics by the following treatment regime: one treatment-period followed by one rest-period represents, i.e. one intervention-cycle that can be repeated at least 3, 4 or to 5 times. </p><p id="p0110" num="0110">Therefore, in another preferred embodiment the present invention relates to a pharmaceutical combination composition comprising at least one renin- 
<!-- EPO <DP n="47"/>-->
 angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein one intervention-cycle is repeated at least 3, 4 or 5 times. </p><p id="p0111" num="0111">Another object of the present invention relates to a pharmaceutical combination composition comprising at least one renin-angiotensin- aldosterone system inhibitor selected from the group consisting of, but not limited to, renin inhibitor, angiotensin-converting enzymeinhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflam matory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein one intervention-cycle is repeated at least 3, 4 or 5 times. </p><p id="p0112" num="0112">Another object of the present invention relates to a pharmaceutical combination composition comprising at least one angiotensin II receptor antagonist, selected from the grou p cons isti ng of, but not l i m ited to , azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures 
<!-- EPO <DP n="48"/>-->
 thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein one intervention-cycle is repeated at least 3, 4 or 5 times. Another object of the present invention relates to a pharm aceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein one intervention-cycle is repeated at least 3, 4 or 5 times. </p><p id="p0113" num="0113">Another object of the present invention relates to a pharmaceutical combination composition comprising telmisartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 20mg and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects wherein one intervention-cycle is repeated at least 3, 4 or 5 times. </p><p id="p0114" num="0114">The authors of the present invention surprisingly found out that the pharmaceutical composition according to the present invention, which substantially decrease arterial age, additionally reveal two unexpected findings: </p><p id="p0115" num="0115">1 ) Efficacy of treatment is similar even in older subjects than in much younger subjects. </p><p id="p0116" num="0116"> 2) Older subjects still have a substantial capacity for improvement of arterial functions or in other words for reduction of arterial age. 
<!-- EPO <DP n="49"/>-->
 Therefore, it could be concluded that the use of pharmaceutical composition according to the present invention is efficient in a wide range of years/ages, and that it could be started later in life (for example at age 50 or even later) with the same or substantially the same expected rate of success. </p><p id="p0117" num="0117">It is well known from the state of the art that functional and morphological properties of arterial wall have high predictive values and have important causal role on worsening or occurrence of cardiovascular disorders. At the same time it is well known that age (chronological or biological age) is one of the most important risk factor for the worsen ing or occurrence of cardiovascular disorders. On the other hand, it is also well known that cardiovascular disorders themselves simultaneously accelerate the arterial ageing and biological ageing. Hence, it is clear from the mentioned above that arterial age is a risk factor for cardiovascular disorders. Therefore, the reduction and reversal of arterial age resu lts in decreased risk for cardiovascular disorders. Putting all these facts together, it can be concluded that improvement in arterial wall properties should be pivotal aim in decreasing both arterial age and risk for cardiovascular disorder. By said approach simultaneous achievement of two tremendously important aims: </p><p id="p0118" num="0118"> - decreasing arterial age and </p><p id="p0119" num="0119"> - decreasing occurrence of cardiovascular disorders </p><p id="p0120" num="0120">are assured and thereby extending the duration and quality of life. </p><p id="p0121" num="0121">In another preferred embodiment, the present invention is a pharmaceutical combination composition comprising at least one renin-angiotensin- aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. 
<!-- EPO <DP n="50"/>-->
 In another preferred embodiment, the present invention is a pharmaceutical combination composition comprising at least one renin-angiotensin- aldosterone system inhibitor in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti- inflam matory agent, an antioxidant or any m ixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0122" num="0122">In another preferred embodiment, the present invention is a pharmaceutical combination composition comprising at least one renin-angiotensin- aldosterone system inhibitor selected from the group consisting of, but not limited to, renin inhibitor, angiotensin-converting enzyme inhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0123" num="0123">In another preferred embodiment, the present invention is a pharmaceutical combination composition comprising at least one angiotensin II receptor antagonist, selected from the group consisting of, but not limited to, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, in a subtherapeutic daily dose and optionally at least one other active agent selected from the group 
<!-- EPO <DP n="51"/>-->
 consisting of an anti-inflammatory agent, an antioxidant or any mixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. In another preferred embodiment, the present invention is a pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0124" num="0124">In another preferred embodiment, the present invention is a pharmaceutical combination composition comprising telmisartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 20mg and optionally at least one other active agent selected from the group consisting of an antiinflammatory agent, an antioxidant or any mixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0125" num="0125">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising at least one renin-angiotensin- aldosterone system inhibitor as defined above in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent as defined above, an antioxidant as defined above or any mixtures thereof. </p><p id="p0126" num="0126">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising at least one angiotensin-ll-receptor blocker as defined above in a subtherapeutic daily dose and optionally at 
<!-- EPO <DP n="52"/>-->
 least one other active agent selected from the group consisting of an antiinflammatory agent as defined above, an antioxidant as defined above or any mixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0127" num="0127">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and acetylsalicylic acid and coenzyme Q10 in any pharmaceutically acceptable form. </p><p id="p0128" num="0128">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and acetylsalicylic acid and coenzyme Q10 in any pharmaceutically acceptable form. </p><p id="p0129" num="0129">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and resveratrol or any pharmaceutically acceptable salts thereof and coenzyme Q 1 0 in any pharmaceutically acceptable form. </p><p id="p0130" num="0130">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and resveratrol or any pharmaceutically acceptable salts thereof and coenzyme Q10 in any pharmaceutically acceptable form. </p><p id="p0131" num="0131">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically 
<!-- EPO <DP n="53"/>-->
 acceptable salts thereof in a subtherapeutic daily dose and acetylsalicylic acid. </p><p id="p0132" num="0132">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and acetylsalicylic acid. </p><p id="p0133" num="0133">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and resveratrol or any pharmaceutically acceptable salts thereof. </p><p id="p0134" num="0134">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and resveratrol or any pharmaceutically acceptable salts thereof. </p><p id="p0135" num="0135">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and coenzyme Q10 in any pharmaceutically acceptable form. </p><p id="p0136" num="0136">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and coenzyme Q10 in any pharmaceutically acceptable form. 
<!-- EPO <DP n="54"/>-->
 In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose. In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg. </p><p id="p0137" num="0137">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and acetylsalicylic acid and coenzyme Q10 in any pharmaceutically acceptable for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0138" num="0138">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and acetylsalicylic acid and coenzyme Q10 in any pharmaceutically acceptable for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0139" num="0139">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and resveratrol or any pharmaceutically acceptable salts thereof and coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. 
<!-- EPO <DP n="55"/>-->
 In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and resveratrol or any pharmaceutically acceptable salts thereof and coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0140" num="0140">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and acetylsalicylic acid for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0141" num="0141">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and acetylsalicylic acid for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and resveratrol or any pharmaceutically acceptable salts thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0142" num="0142">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and resveratrol or any pharmaceutically acceptable salts thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. 
<!-- EPO <DP n="56"/>-->
 In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose and coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0143" num="0143">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0144" num="0144">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a subtherapeutic daily dose for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0145" num="0145">In another preferred embodiment, the present invention is the pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40 mg for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0146" num="0146">The term pharmaceutical combination composition according to the present invention may mean that each component is adm inistered to the patient separately in an individual dosage form simultaneously, separately or sequentially in any order. The present invention furthermore relates to a commercial package comprising the pharmaceutical combination composition according to the present invention together with instructions for simultaneous, separate or sequential use. 
<!-- EPO <DP n="57"/>-->
 Alternatively the term pharmaceutical combination composition according to the present invention may mean that all or just some components of the composition are administered to the subject in the same unit dosage form. The combination of two or more active agents in the same pharmaceutical combination composition provides the additional advantage of reducing the frequency of administration of a dosage, thereby increasing the safety of the therapy and it is more patient friendly. </p><p id="p0147" num="0147">Therefore, in a preferred embodiment, the further object of the present invention relates to the pharmaceutical combination composition comprising a pharmaceutical combination composition according to the present invention together with one or more pharmaceutically acceptable excipient. The term 'pharmaceutically acceptable' as employed herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings or, as the case may be, an animal without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The term 'pharmaceutically acceptable excipient' means a component of a ph arm aceut ica l prod uct that i s not an active i n g red ient. U sefu l pharmaceutically acceptable excipients of the present invention include, but are not limited to, diluents, disintegrants, binders, lubricants, surfactants, pH modifiers, antiadherants, pigments, colorants and the like, and any combinations thereof. </p><p id="p0148" num="0148">The pharmaceutical combination composition according to the present invention may be administered to the patient by any known route of administration such as for example peroral (mouth), topical (skin), parenteral (skin or mucous membrane), transmucosal (nasal, buccal/sublingual, vaginal, occular, rectal) or inhalation. The pharmaceutical combination composition 
<!-- EPO <DP n="58"/>-->
 according to the present invention may be useful for immediate-, delayed-, modified-, sustained-, extended-, pulsed-, continous- or controlled-release applications. The pharmaceutical combination composition according to the present invention may be prepared by any process known from the state of the art. </p><p id="p0149" num="0149">The pharmaceutical combination composition according to the present invention suitable for peroral administration may take the form of, but is not limited to, solution, suspension, emulsion, tablet, pill, gel, syrup, elixir, capsule, powder, liquid or solid crystal, paste, and the like. </p><p id="p0150" num="0150">The pharmaceutical combination composition according to the present invention suitable for topical administration may take the form of, but are not limited to, cream, gel, liniment or balm, lotion, ointment, ear drops, eye drops, skin patch and the like. </p><p id="p0151" num="0151">The pharmaceutical combination composition according to the present invention suitable for parenteral administration may refer to modes of administration which include, but are not limited to, intradermal, intraosseous, intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. </p><p id="p0152" num="0152">The pharmaceutical combination composition according to the present invention suitable for inhalation may take the form of, but is not limited to, aerosol, inhaler, nebulizer, vaporizer and the like. </p><p id="p0153" num="0153">The pharmaceutical combination composition according to the present invention may be in the form of suppositories such as for example rectal or vaginal suppositories. 
<!-- EPO <DP n="59"/>-->
 To conclude, the inventors of the present application surprisingly found out that arterial ageing (in particular typical functional and morphological characteristics of arterial wall that can be measured by standard and widely used methods) can be prevented, reduced or reversed by administering the pharmaceutical combination composition according to the present invention. The achieved beneficial arterial characteristics were not accompanied by the primary action of renin-angiotensin-aldosterone system inhibitor i.e. decrease of blood pressure. Unexpectedly, the improvement in age-related characteristics in the observed population was achieved already after short- term treatment (for example at least one month) and again, unexpectedly, persists at important level approximately to 12 months after discontinuation of treatment. The unique efficacy profile of said composition of the present invention allows a cyclic treatment consisting of a short term treatment-period followed by a long term rest-period during which beneficial arterial characteristics are still present. </p><p id="p0154" num="0154">In particular, the present invention comprises the following preferred embodiments: 1 . A pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group consisting of, renin inhibitor, angiotensin-converting enzymeinhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0155" num="0155">2. A pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group 
<!-- EPO <DP n="60"/>-->
 consisting of, renin inhibitor, angiotensin-converting enzymeinhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0156" num="0156">3. A pharmaceutical combination composition according to items 1 and 2 wherein one intervention-cycle is repeated at least 3 to 5 times. </p><p id="p0157" num="0157">4. The pharmaceutical combination composition according to items 1 to 3 wherein the subtherapeutic daily dose is between 1 and 50%, preferably between 1 and 25% of daily recommended therapeutic dose. 5. The pharmaceutical combination composition according to anyone of items 1 to 4 wherein renin-angiotensin-aldosterone system inhibitor is angiotensin II receptor antagonist, selected from the group consisting of, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof. </p><p id="p0158" num="0158">6. The pharmaceutical combination composition according to item 5 wherein angiotensin II receptor antagonist is valsartan or any pharmaceutically acceptable salts. 
<!-- EPO <DP n="61"/>-->
 7. The pharmaceutical combination composition according to anyone of items 1 to 6 wherein anti-inflammatory agent is selected from the group consisting of acetylsalicylic acid and resveratrol. 8. The pharmaceutical combination composition according to anyone of items 1 to 7 wherein antioxidant is coenzyme Q10 or any analogues thereof. </p><p id="p0159" num="0159">9. The pharmaceutical combination composition according to anyone of items 1 to 8 wherein one intervention-cycle consists of one treatment-period lasting between about 2 weeks to about 3 months, preferably between about 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month and one rest-period lasting 12 months, preferably between 6 and 12 months. 10. The pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form. 1 1 . The pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0160" num="0160">12. The pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. 
<!-- EPO <DP n="62"/>-->
 13. The pharmaceutical combination composition according to any one of items 1 to 12 further comprising one or more pharmaceutically acceptable excipient. In particular, the present invention com prises the following preferred embodiments: </p><p id="p0161" num="0161">1 . A pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group consisting of, renin inhibitor, angiotensin-converting enzymeinhibitor and angiotensin II receptor antagonist and any combinations thereof in a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures thereof for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0162" num="0162">2. A pharmaceutical combination composition comprising at least one renin-angiotensin-aldosterone system inhibitor, selected from the group consisting of, renin inhibitor, angiotensin-converting enzymeinhibitor and angiotensin II receptor antagonist and any combinations thereof i n a subtherapeutic daily dose and optionally at least one other active agent selected from the group consisting of an anti-inflammatory agent, an antioxidant or any m ixtures thereof for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0163" num="0163">3. A pharmaceutical combination composition according to items 1 and 2 wherein one intervention-cycle is repeated at least 3 to 5 times. 
<!-- EPO <DP n="63"/>-->
 4. The pharmaceutical combination composition according to items 1 to 3 wherein the subtherapeutic daily dose is between 1 and 50%, preferably between 1 and 25% of daily recommended therapeutic dose. 5. The pharmaceutical combination composition according to anyone of items 1 to 4 wherein renin-angiotensin-aldosterone system inhibitor is angiotensin II receptor antagonist, selected from the group consisting of, azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof, preferably azilsartan, losartan, telmisartan, olmesartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof, more preferably losartan, telmisartan, azilsartan, candesartan and valsartan and any pharmaceutically acceptable salts or esters thereof and even more preferably valsartan and telmisartan and any pharmaceutically acceptable salts or esters thereof. </p><p id="p0164" num="0164">6. The pharmaceutical combination composition according to item 5 wherein angiotensin II receptor antagonist is valsartan or any pharmaceutically acceptable salts. </p><p id="p0165" num="0165">7. The pharmaceutical combination composition according to anyone of items 1 to 6 wherein anti-inflammatory agent is selected from the group consisting of acetylsalicylic acid and resveratrol. 8. The pharmaceutical combination composition according to anyone of items 1 to 7 wherein antioxidant is coenzyme Q10 or any analogues thereof. </p><p id="p0166" num="0166">9. The pharmaceutical combination composition according to anyone of items 1 to 8 wherein one intervention-cycle consists of one treatment-period lasting between about 2 weeks to about 3 months, preferably between about 
<!-- EPO <DP n="64"/>-->
 2 weeks to about 2 months and more preferably between about 2 weeks to about 1 month and one rest-period lasting 12 months, preferably between 6 and 12 months. 10. The pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form. 1 1 . The pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </p><p id="p0167" num="0167">12. The pharmaceutical combination composition comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40mg and optionally acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form for use in decreasing occurrence of cardiovascular disorders in apparently healthy subjects. </p><p id="p0168" num="0168">13. The pharmaceutical combination composition according to any one of items 1 to 12 further comprising one or more pharmaceutically acceptable excipient. </p><p id="p0169" num="0169">The present invention is illustrated in further details with reference to the following examples. However, the scope of the present invention is not limited to these examples. 
<!-- EPO <DP n="65"/>-->
 Example 1 a) Subjects and experimental design </p><p id="p0170" num="0170"> Forty apparently healthy male individuals (42.5 ± 2.5 years) were recruited in double blind, randomized study. Inclusion criteria were: </p><p id="p0171" num="0171">a) chronological age between 20 and 65 years and </p><p id="p0172" num="0172">b) no history of cardiovascular disease. </p><p id="p0173" num="0173">The participants in the study had a Framingham risk factor for a CHD (10 years) of 6.9. </p><p id="p0174" num="0174">The pharmaceutical combination composition comprising valsartan (as a representative of angiotensin II receptor antagonist) and following pharmaceutically acceptable excipients microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and iron oxide was used. </p><p id="p0175" num="0175">The control group (n = 20) received placebo, while the test group (n = 20) received subtherapeutic daily dose of valsartan - 20 mg daily (the recommended therapeutic daily dose is between 80 to 320 mg) during a period of 1 month - 30 days. </p><p id="p0176" num="0176">All subjects underwent clinical examination, blood pressure measurements (Welch Allyn Spiedel&amp; Keller automated sphygmomanometer) and ultrasound measurement of flow-mediated dilatation of brachial artery (FMD), pulse-wave velocity (PVW) and β-stiffness of carotid artery at inclusion (0<sup>th</sup> day) and after 1 month (30<sup>th</sup> day) of the study. Fasting blood samples were taken at the beginning and at the end of the study for laboratory analysis. 
<!-- EPO <DP n="66"/>-->
 Blood glucose, electrolytes and cholesterol were obtained using the VITRO 5.1 FS Chemical system (Ortho Clinical Diagnostics, Inc.). b) Ultrasound measurements </p><p id="p0177" num="0177">U ltrasound measurements were performed by a single exam iner using AlokaProSound Alpha 10 echo-machine. Endothelial function was measured by means of FMD on the brachial artery according to FMD guidelines (Corretti MC et al. Guidelines for the ultrasound assessment of endothelial- dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65). The echo-machine continuously tracked and recorded the brachial artery diameter. Following the measurement of baseline brachial artery diameter (1 min), the forearm blood pressure cuff was inflated to 50 mmHg above the systolic pressure for 4 min. After the occlusion period, the cuff was rapidly deflated, inducing reactive hyperemia, and the brachial artery diameter was recorded for 3 min. At the end of the measurement, the machine automatically provided the values of FMD. </p><p id="p0178" num="0178"> The measurements of PVW and β-stiffness were performed on the right common carotid artery. The Aloka ultrasound device was also equipped with special software for automatic determination of the PVW and beta-stiffness through the analysis of pulse waves (Carerj S et al. Normal vascular aging evaluated by a new tool: e-tracking. Eur J Echocardiography 2006; suppl: S 49). c) Statistical analysis </p><p id="p0179" num="0179"> All values were expressed as arithmetic mean ± SEM and were normally distributed. Differences between values recorded at the beginning (0<sup>th</sup> day) and at the end of the study (30<sup>th</sup> day) were determined by one-way analysis of variance (ANOVA). When a significant interaction was present, the Bonferroni post-test was performed. A P-value of less than 0.05 was 
<!-- EPO <DP n="67"/>-->
 considered significant. All statistical analyses were performed using Graph Pad Prism 5.0 software. d) Results </p><p id="p0180" num="0180"> 5 Characteristics of the individuals at the beginning and at the end of the study in both groups are shown in Table 1 . </p><p id="p0181" num="0181">Table 1 : Subject characteristics in the placebo and in the test group </p><p id="p0182" num="0182">Placebo (n<sup>:</sup> =20) Valsartan 20 mg (n=20) </p><p id="p0183" num="0183"> value</p><p id="p0184" num="0184">0<sup>th</sup> day 30<sup>th</sup> day 0<sup>th</sup> day 30<sup>th</sup> day </p><p id="p0185" num="0185"> Systolic BP (mmHg) 122.2 ± 1.3 121.2 ± 1.0 123.7 ± 2.0 119.8 ± 1.8 0. 25</p><p id="p0186" num="0186">Diastolic BP (mmHg) 73.5 ± 1.6 73.4 ± 1.4 76.5 ± 1.6 74.2 ± 1.3 0. 41</p><p id="p0187" num="0187">Heart rate (b.p.m.) 61.8 ± 1.9 61.2 ± 1.6 64.4 ± 2.0 62.2 ± 1.4 0. 32</p><p id="p0188" num="0188">Plasma glucose (mmol/l) 4.9 ± 0.2 4.9 ± 0.1 4.9 ± 0.1 4.7 ± 0.2 0. 34</p><p id="p0189" num="0189">All values are expressed as arithmetic mean ± SEM. BP: blood pressure; b.p.m.: beats per minute </p><p id="p0190" num="0190">No statistically significant differences in the listed parameters (systolic and diastolic blood pressure, heart rate, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and glucose concentration) were observed between5 the placebo and test group. </p><p id="p0191" num="0191">Table 2: Functional and morphological parameters before and after treatment </p><p id="p0192" num="0192"> Before After Improvement treatment treatment </p><p id="p0193" num="0193"> FMD (%) 2.11 5.40 +156.0% </p><p id="p0194" num="0194"> PWV (m/s) 5.80 5.41 -7.2% </p><p id="p0195" num="0195"> β- stiffness (U) 7.28 6.40 -13.7% </p><p id="p0196" num="0196">Arterial age </p><p id="p0197" num="0197"> according to age </p><p id="p0198" num="0198"> 45.0 38.0 -7.0 </p><p id="p0199" num="0199"> normogram </p><p id="p0200" num="0200"> (years) 
<!-- EPO <DP n="68"/>-->
 The results presented in Table 2 and Figure 1 show that FMD increased by 156.0% (P&lt;0.001 ; Figure 1A), β-stiffness of the carotid artery decreased by 13.7% (PO.01 ; Figure 1 B) and PVW decreased by 7.2% (PO.01 ; Figure 1 B) after 1 month treatment period. The substantial improvement was observed in each subject of the test group in all measured ultrasound parameters. No significant changes in described parameters in the placebo group throughout the study were observed. </p><p id="p0201" num="0201">Example 2 </p><p id="p0202" num="0202">Follow-up ultrasound measurements were repeated after 5, 7 and 8 months of therapy discontinuation in all participants of Example 1 . </p><p id="p0203" num="0203">Table 3: Residual improvement expressed in % of effect achieved after 1 month of treatment </p><p id="p0204" num="0204"><img id="imgf000068_0001" he="63" wi="138" file="imgf000068_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0205" num="0205">The important prolonged effect was clearly revealed (Figure 2). 
<!-- EPO <DP n="69"/>-->
 Example 3 </p><p id="p0206" num="0206">By using age-related normogram (according to the methods described in Jurasic MJ et al. Beta stiffness - setting age standards. Acta Clin Croat 2009;48:253-8; and Carerj S. Normal vascular ageing evaluated by a new tool: e-tracking. Eur J Echocardiography 2006; suppl 1 :S49. Carerj S et al. Eur J Echocardiography 2006; suppl: S 49) the "biological" arterial age in participants according to Example 1 after 1 month of treatment and according to Example 2 after 5, 7 and 8 months after discontinuation of treatment was calculated (Figure 3). </p><p id="p0207" num="0207">Example 4 a) Subjects and experimental design </p><p id="p0208" num="0208">30 apparently healthy male individuals (35.6 ± 4.1 years) were included double blind, randomised study. They had no history of cardiovascular disease. The participants in the study had a Framingham risk factor for a CHD (10 years) of 6.9. The control group (n=15) received placebo, while the test group (n = 15) received valsartan - 20 mg daily. </p><p id="p0209" num="0209">Application of the same pharmaceutical combination composition as in Example 1 , same ultrasound measurement, same statistical analysis. 
<!-- EPO <DP n="70"/>-->
</p><p id="p0210" num="0210">Results </p><p id="p0211" num="0211">Table 4: Functional and morphological parameters before and after treatment </p><p id="p0212" num="0212"><img id="imgf000070_0001" he="57" wi="149" file="imgf000070_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/>
 The results presented in Table 4 and in Figure 4 show that FMD increased by 137.5% (P&lt;0.001 ; Figure 4A), β-stiffness of the carotid artery decreased by 1 1 .3% (P&lt;0.05; Figure 4B) and PWV decreased by 16.6% (Figure 4C) after 1 month treatment period. No significant changes in described parameters in the placebo group throughout the study were observed. </p><p id="p0213" num="0213">Example 5 </p><p id="p0214" num="0214">Follow-up ultrasound measurements were repeated after 3, 8 and 10 months of therapy discontinuation in all participants of Example 4. 
<!-- EPO <DP n="71"/>-->
</p><p id="p0215" num="0215">Table 5: Residual improvement expressed in % of effect achieved after 1 month of treatment </p><p id="p0216" num="0216"><img id="imgf000071_0001" he="57" wi="149" file="imgf000071_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0217" num="0217">The important prolonged effect was clearly revealed (Figure 5). Example 6: </p><p id="p0218" num="0218">Results of repetition of treatment period after rest period of 12 months (ten participants, valsartan 20 mg daily for 1 month - 30 days). </p><p id="p0219" num="0219">Table 5: Improvement on FMD, PWV and β-stiffness achieved after 1 month of treatment (1 . intervention) and a further 1 month treatment (2. intervention) after a rest period of 12 months </p><p id="p0220" num="0220"><img id="imgf000071_0002" he="39" wi="153" file="imgf000071_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0221" num="0221"> The results are summarized in Figure 6. Evidently, the beneficial effects be repeated. 
</p></description><claims mxw-id="PCLM44852407" ref-ucid="WO-2012116996-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="72"/>--> Claims </claim-statement><claim id="clm-0001" num="1"><claim-text>1 . A pharmaceutical composition comprising </claim-text><claim-text> at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose for use in the prevention, reduction or reversal of arterial ageing in apparently healthy subjects. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. A pharmaceutical composition comprising </claim-text><claim-text> at least one renin-angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose for use in decreasing the occurrence of </claim-text><claim-text>cardiovascular disorders in apparently healthy subjects. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The pharmaceutical composition according to claim 1 or 2, wherein at least one renin-angiotensin-aldosterone inhibitor is selected from the group consisting of renin inhibitor, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist and combinations thereof. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the renin-angiotensin-aldosterone system inhibitor is an angiotensin</claim-text><claim-text>II receptor antagonist. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the angiotensin II receptor antagonist is selected from the group consisting of azilsartan, losartan, eprosartan, irbesartan, olmesartan, candesartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters and any combinations thereof. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the angiotensin II receptor antagonist is selected from the group consisting of azilsartan, losartan, olmesartan, candesartan, valsartan, <!-- EPO <DP n="73"/>--> telmisartan, and any pharmaceutically acceptable salts or esters, and combinations thereof. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the angiotensin II receptor antagonist is selected from the group consisting of azilsartan, losartan, candesartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters, and combinations thereof. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the angiotensin II receptor antagonist is selected from the group consisting of losartan, valsartan, telmisartan, and any pharmaceutically acceptable salts or esters, and combinations thereof. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the angiotensin II receptor antagonist is selected from the group consisting of losartan, valsartan, and any pharmaceutically acceptable salts or esters, and combinations thereof. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The pharmaceutical composition according to any one of claims 1 to 9, wherei n the ang iotens in I I receptor antagon ist is valsartan or any pharmaceutically acceptable salt thereof, preferably valsartan. </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1 . The pharmaceutical composition according to any one of claims 1 to 9, wherein the angiotensin II receptor antagonist is losartan or any pharmaceutically acceptable salt thereof, preferably losartan potassium. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The pharmaceutical composition according to any one of claims 1 to 1 1 , wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone system inhibitor does not substantially lower the systolic blood pressure. <!-- EPO <DP n="74"/>--> </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>12, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone system inhibitor does not substantially lower the diastolic blood pressure. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>13, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone system inhibitor does not lower the systolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 6%, most preferably more than 4%. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>14, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone system inhibitor does not lower the systolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 6%, most preferably more than 4%, when administered for at least 10 days, preferably at least 14 days, more preferably at least 1 month. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>15, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone system inhibitor does not lower the diastolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more than 8%, most preferably more than 5%. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>16, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone system inhibitor does not lower the diastolic blood pressure in a subject by more than 15%, preferably more than 10%, more preferably more <!-- EPO <DP n="75"/>--> than 8%, most preferably more than 5%, when administered for at least 10 days, preferably at least 14 days, more preferably at least 1 month. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The pharmaceutical composition according to any one of claims 1 to 17, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone inhibitor is between 1 and 50%, preferably between 1 and 25% of the daily recommended therapeutic dose. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. The pharmaceutical composition according to any one of claims 1 to 18, wherein the subtherapeutic daily dose of the renin-angiotensin- aldosterone inhibitor is between 1 and 75 mg, between 1 and 60 mg, between 1 and 50 mg, between 1 and 45 mg, between 1 and 40 mg, and/or between 1 and 25 mg. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. The pharmaceutical composition according to any one of claims 1 to 19, wherein the renin-angiotensin-aldosterone is valsartan or any </claim-text><claim-text>pharmaceutically acceptable salts or esters thereof, and the subtherapeutic daily dose is between 1 and 75 mg, preferably between 1 and 60 mg, more preferably between 1 and 50 mg, still more preferably between 1 to 40 mg, most preferably between 10 to 30 mg, particularly preferably 20 mg. </claim-text></claim><claim id="clm-0021" num="21"><claim-text>21 . The pharmaceutical composition according to any one of claims 1 to 19, wherein the renin-angiotensin-aldosterone is telmisartan or any pharmaceutically acceptable salts or esters thereof, and the subtherapeutical dose thereof is between 1 to 40 mg, preferably between 1 to 20 mg, most preferably 20 mg. </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. The pharmaceutical composition according to any one of claims 1 to 19, wherein the renin-angiotensin-aldosterone is losartan or any </claim-text><claim-text>pharmaceutically acceptable salts or esters thereof, and the subtherapeutical <!-- EPO <DP n="76"/>--> dose thereof is between 1 to 40 mg, preferably between 1 to 30 mg, most preferably 20 mg. </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. The pharmaceutical composition according to any one of claims 1 to 22, wherein the apparently healthy subjects are human subjects. </claim-text></claim><claim id="clm-0024" num="24"><claim-text>24. The pharmaceutical combination composition according to any one of claims 1 to 23, wherein the apparently healthy subjects have a low </claim-text><claim-text>cardiovascular risk. </claim-text></claim><claim id="clm-0025" num="25"><claim-text>25. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>24, wherein the apparently healthy subjects have a risk for a coronary heart disease (10-year risk) according to the Framingham Risk Score of 10% or less, preferably 8% or less, more preferably 5% or less. </claim-text></claim><claim id="clm-0026" num="26"><claim-text>26. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>25, wherein the subject does not have a cardiovascular disorder selected from the group consisting of ischemic heart disease, carotid and intracerebral artery disease, peripheral arterial disease, aortic aneurism, and any combinations thereof. </claim-text></claim><claim id="clm-0027" num="27"><claim-text>27. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>26, wherein the cardiovascular disorder is selected from the group consisting of myocardial infarction, stroke, dementia, critical limb ischemia, aortic aneurism, and any combinations thereof, preferably from myocardial infarction, stroke, vascular dementia and any combinations thereof. </claim-text></claim><claim id="clm-0028" num="28"><claim-text>28. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>27, wherein the cardiovascular disorder is selected from the group consisting <!-- EPO <DP n="77"/>--> of from myocardial infarction, stroke, vascular dementia and any </claim-text><claim-text>combinations thereof. </claim-text></claim><claim id="clm-0029" num="29"><claim-text>29. The pharmaceutical composition according to any one of claims 1 to 28, wherein the treatment period is at least one week, at least 2 weeks, preferably between 2 weeks to 3 months, more preferably between 2 weeks and 2 months, and more preferably between 2 weeks and 1 month, and most preferably after treatment for 1 month. </claim-text></claim><claim id="clm-0030" num="30"><claim-text>30. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>29, wherein the flow-mediated dilatation of brachial artery (FMD) after a period of treatment, preferably after 1 month of treatment, is increased compared to the beginning of the treatment. </claim-text></claim><claim id="clm-0031" num="31"><claim-text>31 . The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>30, wherein the pulse-wave velocity (PWV) after a period of treatment, preferably after 1 month of treatment, is decreased compared to the beginning of the treatment. </claim-text></claim><claim id="clm-0032" num="32"><claim-text>32. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>31 , wherein the β-stiffness of carotid artery after a period of treatment, preferably after 1 month of treatment, is decreased compared to the beginning of the treatment. </claim-text></claim><claim id="clm-0033" num="33"><claim-text>33. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>32, wherein both the pulse-wave velocity (PWV) and the β-stiffness of carotid artery after a treatment period, preferably after 1 month of treatment, is decreased compared to the beginning of the treatment. <!-- EPO <DP n="78"/>--> </claim-text></claim><claim id="clm-0034" num="34"><claim-text>34. The pharmaceutical composition according to any one of claims 1 to 30, wherein the FMD increases by at least 25%, preferably at least 50%, more preferably at least 100%, still more preferably at least 125%, most preferably at least 150%, after a treatment period, preferably after 1 month of treatment. </claim-text></claim><claim id="clm-0035" num="35"><claim-text>35. The pharmaceutical composition according to any one of claims 1 to 29, 31 and 33, wherein the PWV decreases by at least 1 %, preferably at least 3%, more preferably at least 5%, most preferably at least 7% after a treatment period, preferably 1 month of treatment. </claim-text></claim><claim id="clm-0036" num="36"><claim-text>36. The pharmaceutical composition according to any one of claims 1 to 29, 32 and 33, wherein the β-stiffness decreases by at least 3%, preferably at least 5%, more preferably at least 10%, and most preferably at least 13%, after a treatment period, preferably after 1 month of treatment. </claim-text></claim><claim id="clm-0037" num="37"><claim-text>37. The pharmaceutical composition according to any one of claims 1 to 36, wherein the reduction or reversal of arterial aging after a period of treatment persists in a substantial amount for at least 1 month, preferably 1 months, more preferably at least 5 months, still more preferably at least 7 months, most preferably at least 10 months, particularly preferably for approximately 12 months after discontinuation of the treatment. </claim-text></claim><claim id="clm-0038" num="38"><claim-text>38. The pharmaceutical composition according to any one of claims 1 to 37, wherein after discontinuation of the treatment for at least 1 months the residual improvement of the FMD is at least 15%, preferably at least 25%, more preferably at least 35%, most preferably at least 45% based on the increase of the FMD after a period of treatment. <!-- EPO <DP n="79"/>--> </claim-text></claim><claim id="clm-0039" num="39"><claim-text>39. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>38, wherein after discontinuation of the treatment for at least 3 months the residual improvement of the FMD is at least 15%, preferably at least 25%, more preferably at least 35%, most preferably at least 45% based on the increase of the FMD after a period of treatment. </claim-text></claim><claim id="clm-0040" num="40"><claim-text>40. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>39, wherein after discontinuation of the treatment for at least 5 months the residual improvement of the FMD is at least 15%, preferably at least 25%, more preferably at least 35%, most preferably at least 45% based on the increase of the FMD after a period of treatment. </claim-text></claim><claim id="clm-0041" num="41"><claim-text>41 . The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>40, wherein after discontinuation of the treatment for at least 7 months the residual improvement of the FMD is at least 10%, preferably at least</claim-text><claim-text>15%, more preferably at least 20%, most preferably at least 25%, even more preferably 30% based on the increase of the FMD after a period of treatment. </claim-text></claim><claim id="clm-0042" num="42"><claim-text>42. The pharmaceutical composition according to any one of claims 1 to 41 , wherein after discontinuation of the treatment for at least 8 months the residual improvement of the FMD is at least 1 %, preferably at least 3%, more preferably at least 5%, most preferably at least 6% based on the increase of the FMD after a period of treatment. </claim-text></claim><claim id="clm-0043" num="43"><claim-text>43. The pharmaceutical composition according to any one of claims 1 to 42, wherein after discontinuation of the treatment for at least 1 months the residual improvement of the PWV is at least 5%, preferably at least 10%, more preferably at least 15%, still more preferably at least 20%, most preferably at least 25% based on the decrease of the PWV after a period of treatment. <!-- EPO <DP n="80"/>--> </claim-text></claim><claim id="clm-0044" num="44"><claim-text>44. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>43, wherein after discontinuation of the treatment for at least 3 months the residual improvement of the PWV is at least 5%, preferably at least 10%, more preferably at least 15%, still more preferably at least 20%, most preferably at least 25% based on the decrease of the PWV after a period of treatment. </claim-text></claim><claim id="clm-0045" num="45"><claim-text>45. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>44, wherein after discontinuation of the treatment for at least 5 months the residual improvement of the PWV is at least 5%, preferably at least 10%, more preferably at least 15%, most preferably at least 20%, even more preferably at least 25%, based on the decrease of the PWV after a period of treatment. </claim-text></claim><claim id="clm-0046" num="46"><claim-text>46. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>45, wherein after discontinuation of the treatment for at least 7 months the residual improvement of the PWV is at least 2%, preferably at least 4%, more preferably at least 6%, most preferably at least 8% based on the decrease of the PWV after a period of treatment. </claim-text></claim><claim id="clm-0047" num="47"><claim-text>47. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>46, wherein after discontinuation of the treatment for at least 8 months the residual improvement of the PWV is at least 0.5%, preferably at least 1 %, more preferably at least 1 .5%, most preferably at least 2%, even more preferably 2.5% based on the decrease of the PWV after a period of treatment. </claim-text></claim><claim id="clm-0048" num="48"><claim-text>48. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>47, wherein after discontinuation of the treatment for at least 1 months <!-- EPO <DP n="81"/>--> the residual improvement of the β-stiffness is at least 5%, preferably at least 10%, more preferably at least 15%, and most preferably at least 20% based on the decrease of the β-stiffness after a period of treatment. </claim-text></claim><claim id="clm-0049" num="49"><claim-text>49. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>48, wherein after discontinuation of the treatment for at least 3 months the residual improvement of the β-stiffness is at least 5%, preferably at least 10%, more preferably at least 15%, and most preferably at least 20% based on the decrease of the β-stiffness after a period of treatment. </claim-text></claim><claim id="clm-0050" num="50"><claim-text>50. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>49, wherein after discontinuation of the treatment for at least 5 months the residual improvement of the β-stiffness is at least 5%, preferably at least 10%, more preferably at least 15%, and most preferably at least 20% based on the decrease of the β-stiffness after a period of treatment. </claim-text></claim><claim id="clm-0051" num="51"><claim-text>51 . The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>50, wherein after discontinuation of the treatment for at least 7 months the residual improvement of the β-stiffness is at least 1 %, preferably at least 3%, more preferably at least 5%, and most preferably at least 8% based on the decrease of the β-stiffness after a period of treatment. </claim-text></claim><claim id="clm-0052" num="52"><claim-text>52. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>51 , wherein after discontinuation of the treatment for at least 8 months the residual improvement of the β-stiffness is at least 0.5%, preferably at least 1 %, more preferably at least 1 .5%, and most preferably at least 2% based on the decrease of the β-stiffness after a period of treatment. </claim-text></claim><claim id="clm-0053" num="53"><claim-text>53. The pharmaceutical composition according to any one of claims 38 to 52, wherein the treatment period is 1 month. <!-- EPO <DP n="82"/>--> </claim-text></claim><claim id="clm-0054" num="54"><claim-text>54. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>53, wherein the prevention, reduction or reversal of arterial aging is achieved by a repeated intervention cycle comprising at least one treatment-period followed by at least one rest-period, which is preferably repeated at least once, more preferably 2, 3, 4 or 5 times. </claim-text></claim><claim id="clm-0055" num="55"><claim-text>55. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>54, wherein the treatment-period lasts at least one week, at least two weeks, preferably between 2 weeks to 3 months, more preferably between 2 weeks and 2 months, still more preferably between 2 weeks and 1 month, most preferably 1 month. </claim-text></claim><claim id="clm-0056" num="56"><claim-text>56. The pharmaceutical composition according to any one of claims 1 to 55, wherein the rest-period of at least 1 day, preferably at least 1 week, preferably 1 month, more preferably 3 months, still more preferably 6 months, most preferably 10 months, particularly preferably approximately 12 months. </claim-text></claim><claim id="clm-0057" num="57"><claim-text>57. The pharmaceutical composition according to any one of claims 1 to 56, comprising a further active agent, preferably selected from the group consisting of an anti-inflammatory agent, an antioxidant, and combinations thereof. </claim-text></claim><claim id="clm-0058" num="58"><claim-text>58. The pharmaceutical composition according to any one of claims 1 to 57, further comprising an anti-inflammatory agent and an antioxidant, with the proviso that the pharmaceutical composition does not comprise vitamin C or vitamin E. <!-- EPO <DP n="83"/>--> </claim-text></claim><claim id="clm-0059" num="59"><claim-text>59. The pharmaceutical composition according to any one of claims 1 to 57, with the proviso that the pharmaceutical composition does not comprise vitamin C and/or vitamin E. </claim-text></claim><claim id="clm-0060" num="60"><claim-text>60. The pharmaceutical composition according to any one of claims 1 to 59, with the proviso that is does not comprise fluvastatin or any </claim-text><claim-text>pharmaceutically acceptable salts thereof. </claim-text></claim><claim id="clm-0061" num="61"><claim-text>61 . The pharmaceutical composition according to any one of claims 1 to 60, further comprising an anti-inflammatory agent, but not comprising an antioxidant. </claim-text></claim><claim id="clm-0062" num="62"><claim-text>62. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>61 , further comprising an antioxidant and an anti-inflammatory agent, which is not acetylsalicylic acid. </claim-text></claim><claim id="clm-0063" num="63"><claim-text>63. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>62, further comprising an antioxidant, but not comprising an anti-inflammatory agent. </claim-text></claim><claim id="clm-0064" num="64"><claim-text>64. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>63, further comprising an anti-inflammatory agent and/or an antioxidant. </claim-text></claim><claim id="clm-0065" num="65"><claim-text>65. The pharmaceutical composition according any one of claims 1 to 64, wherein the anti-inflammatory agent is selected from the group consisting of acetylsalicylic acid and resveratrol. </claim-text></claim><claim id="clm-0066" num="66"><claim-text>66. The pharmaceutical composition according to any one of claims 1 to 65, wherein the antioxidant is coenzyme Q10 or any analogue thereof. <!-- EPO <DP n="84"/>--> </claim-text></claim><claim id="clm-0067" num="67"><claim-text>67. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>66, wherein the anti-inflammatory agent is acetylsalicylic and the antioxidant is coenzyme Q10. </claim-text></claim><claim id="clm-0068" num="68"><claim-text>68. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>67, wherein acetylsalicylic acid is present in a daily dose of between 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg. </claim-text></claim><claim id="clm-0069" num="69"><claim-text>69. The pharmaceutical composition according to any one of claims 1 to 68, wherein coenzyme Q10 is present in a daily dose of 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg. </claim-text></claim><claim id="clm-0070" num="70"><claim-text>70. The pharmaceutical composition according to any one of claims 1 to 69, comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40 mg, preferably between 10 to 30 mg, most preferably 20 mg, and acetylsalicylic acid, resveratrol and/or coenzyme Q10 in any pharmaceutically acceptable form. </claim-text></claim><claim id="clm-0071" num="71"><claim-text>71 . The pharmaceutical composition according to any one of claims 1 to 70, comprising valsartan or any pharmaceutically acceptable salts thereof in a daily dose between 1 and 40 mg, preferably between 10 to 30 mg, most preferably 20 mg, and acetylsalicylic acid in a daily dose between 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg and/or coenzyme Q10 1 to 200 mg, preferably 50 to 150 mg, most preferably 100 mg. </claim-text></claim><claim id="clm-0072" num="72"><claim-text>72. The pharmaceutical composition according to any one of claims 1 to 71 further comprising one or more pharmaceutically acceptable excipient. <!-- EPO <DP n="85"/>--> </claim-text></claim><claim id="clm-0073" num="73"><claim-text>73. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>72, wherein the composition is in form of a oral dosage form, preferably a solid oral dosage form. </claim-text></claim><claim id="clm-0074" num="74"><claim-text>74. The pharmaceutical composition according to any one of claims 1 to</claim-text><claim-text>73, wherein the first treatment period is 1 month, followed by a rest period of 12 months and a further treatment period of 1 month. </claim-text></claim><claim id="clm-0075" num="75"><claim-text>75. A method for preventing, reducing and reversing arterial ageing in an apparently healthy subject, comprising administering to an apparently healthy subject a pharmaceutical composition at least one renin-angiotensin- aldosterone system inhibitor in a subtherapeutic daily dose. </claim-text></claim><claim id="clm-0076" num="76"><claim-text>76. A method for decreasing the occurrence of cardiovascular disorders in apparently healthy subjects, comprising adm inistering to an apparently healthy subject a pharmaceutical composition comprising at least one renin- angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose. </claim-text></claim><claim id="clm-0077" num="77"><claim-text>77. Use of a pharmaceutical composition comprising at least one renin- angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose in the manufacture of a medicament for preventing, reducing and reversing arterial ageing in an apparently healthy subject. </claim-text></claim><claim id="clm-0078" num="78"><claim-text>78. Use of a pharmaceutical composition comprising at least one renin- angiotensin-aldosterone system inhibitor in a subtherapeutic daily dose, in the manufacture of a medicament for decreasing the occurrence of cardiovascular disorders in apparently healthy subjects. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
